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ABSTRACT 
 
The objective of this project is to explore of the use of the empirical phase diagram approach in 
the formulation development of several forms of vaccines that exist today such as recombinant based 
subunit vaccines and the traditional live attenuated viral vaccines. The chapters in this dissertation 
describe the formulation development of three vaccines. The first is a monovalent recombinant-based 
subunit vaccine targeted against that 2009 pandemic “swine” influenza (Chapter 1). The second is a 
trivalent vaccine consisting of three recombinantly produced proteins from S. pneumonia (Chapter 2). 
The third is a trivalent live viral canine vaccine targeted against canine distemper, parainfluenza and 
kennel cough caused by canine adenovirus type 2 (Chapter 3).  The first aim in each chapter is the 
biophysical characterization of the individual biological entities. This was accomplished by initially by 
fully characterizing each of the antigens using multiple analytical techniques such as intrinsic tryptophan 
fluorescence and circular dichroism spectroscopy and static light scattering experiments among others. 
The ideal preformulation conditions were identified using the empirical phase diagram technique.  
Influenza is a prevalent, highly contagious and sometimes fatal respiratory disease. Vaccination 
provides an effective approach to control the disease, but because of frequent changes in the structure of 
the major surface proteins, there is great need for a technology that permits rapid preparation of new 
forms of the vaccine each year in sufficient quantities. Recently, using a safe, simple, time- and cost-
effective plant viral vector-based transient expression system, the hemagglutinin antigen of H1N1 
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influenza A strain (HAC1), an H1N1 influenza vaccine candidate, has been produced in Nicotiana 
benthamiana plants. As a step towards the generation of a commercially viable subunit influenza vaccine, 
we developed HAC1 formulations in the presence and absence of an aluminum salt adjuvant 
(Alhydrogel®), analyzed their properties, and assessed immunogenicity in an animal model. Biophysical 
properties of HAC1 were evaluated using several spectroscopic and light scattering techniques as a 
function of pH and temperature combined with data analysis using an empirical phase diagram approach. 
Excipients that were potent stabilizers of the recombinant protein were identified using intrinsic 
fluorescence spectroscopy. The adsorptive capacity and thermal stability of the protein on the surface of 
Alhydrogel® were then examined in the presence and absence of selected stabilizers using UV 
absorbance after centrifugation and intrinsic fluorescence spectroscopy, respectively. Immunogenicity 
studies conducted in mice demonstrated that the highest level of serum immune responses 
(hemagglutination-inhibiting antibody titers), with a 100% seropositive rates, were induced by HAC1 in 
the presence of Alhydrogel®, and this response was elicited regardless of the solution conditions of the 
formulation. 
The preformulation of a trivalent recombinant protein based vaccine candidate for protection 
against Streptococcus pneumoniae is described both in the presence and absence of aluminum salt 
adjuvants. The biophysical properties of the three protein-based antigens, fragments of PsaA, StkP and 
PcsB, were studied using several spectroscopic and light scattering techniques. An empirical phase 
diagram was constructed to assess the overall conformational stability of the three antigens as a function 
of pH and temperatures. A variety of excipients were screened based on their ability to stabilize each 
antigen using intrinsic fluorescence spectroscopy and circular dichroism spectroscopy. Sorbitol, sucrose, 
and trehalose stabilized three proteins in solution. The addition of manganese also showed a drastic 
increase in the thermal stability of PsaA in solution. The adsorption and desorption processes of each of 
the antigens to aluminum salt adjuvants were evaluated and the stability of the adsorbed proteins were 
then assessed using intrinsic fluorescence spectroscopy and FTIR spectroscopy. All three proteins showed 
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good adsorption to Alhydrogel. PsaA was destabilized when adsorbed onto Alhydrogel and adding 
sodium phosphate showed a stabilizing effect. PcsB was found to be stabilized when adsorbed to 
Alhydrogel, and no destabilizing or stabilizing effects were seen in the case of StkP. 
The empirical phase diagram based approach was utilized to rapidly identify stabilizing buffer 
conditions and excipients for potential use in a complex trivalent live-virus veterinary vaccine. The 
attenuated versions of canine distemper virus (CDV), canine parainfluenza virus (CPI) and the canine 
adenovirus type 2 (CAV2) were purified separately to enable study of the physical stability of the 
individual viruses. The CDV and CPI viruses were purified using centrifugation and/or sucrose gradient 
techniques, and CAV2 virus was isolated using ammonium sulfate precipitation. The integrity of the three 
viruses was confirmed by transmission electron microscopy and purity was assessed by SDS-PAGE. The 
structural properties and conformational stability of the three viruses were then studied using various 
spectroscopic and light scattering techniques. The data obtained from the various methods were then used 
to construct an empirical phase diagram to characterize the physical stability of the individual viruses as a 
function of pH and temperature. Potential stabilizers were then identified for each virus using an assay 
based on the aggregation state of the viral particles and the conformational state of the viral proteins. 
Sucrose and sorbitol were demonstrated to be promising common stabilizers for all three live attenuated 
viruses. 
In conclusion, the empirical phase diagram approach was used to successfully formulate three 
vaccines in solution and while adsorbed on to the surface of aluminum salt adjuvants. The EPD proves to 
be a robust tool that can aid immensely in the early stages of formulation.  
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Introduction 
 
In combination with public health measures, vaccines have had the most profound beneficial 
effect on the quality of human health since the wide availability of potable water. With the use of 
vaccines in the last century, we have been able to completely eliminate diseases such as small pox and 
rinderpest.1-3 Likewise polio is on the brink of extinction with the advent of the polio vaccine.4  Diseases 
that have claimed millions of lives such as measles, mumps, rubella and pneumonia among several others 
have also been rendered harmless due to the development of vaccines. Table 1 lists a few diseases along 
with the effect that vaccines have had on the mortality caused by these diseases. Most of these vaccines 
have been developed by traditional methods, and are based on the use of attenuated or inactivated forms 
of the disease causing agent to prime the immune system5. The history of vaccines dates back several 
centuries when people in India and China used dried pus from people infected with small pox to inoculate 
healthy people.6 Although not a vaccine as we know it today, this technique, which came to be known as 
variolation, dropped the mortality rates of small pox from 30% to about 2%.3 Soon, the rest of the world 
would learn of this technique and it would even come to be used in the American war for independence.3 
The word “vaccine” comes from the use of vaccinia virus, which Edward Jenner used to protect against 
small pox. This was the first modern vaccine to be developed and it came at a time when scientists had 
even no idea of the existence of viruses.7 But the lessons learned from the distribution mechanisms of the 
small pox vaccine helped Louis Pasteur unravel the concepts of attenuation or weakening of 
microorganisms when passaged through other cell cultures. This led to the development of vaccines 
against rabies and many very successful vaccines in the 20th century such as the ones against measles, 
mumps and rubella. Over the last century, we have learnt a lot about vaccines and how they work. This 
introductory chapter provides an overview of some basic immunology in addition to a brief description of 
the different types of vaccines, and the steps involved in the discovery and development of some of the 
basic types of vaccines.  
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Introduction to Immunology 
 
Vaccines work by “teaching” the immune system to recognize harmful pathogens. To develop 
efficacious vaccines, it is crucial to understand how the immune system does this. The immune system 
has two branches – the innate immune system and the adaptive immune system, which describe non-
specific and specific responses, respectively, towards invading pathogens.8 The innate immune response 
provides the first line of defense against invading pathogen. There are four components to the innate 
immune system.  
1. Anatomic barriers 
2. Physiological barriers 
3. Phagocytic mechanisms 
4. Inflammation 
Examples of anatomic barriers are the mucosal membranes and the skin that cover the interface 
between the environment and the body.9 The skin consists of two distinct layers – the epidermis and the 
dermis. The epidermis consists of several layers of epithelial cells. The outermost layers are primarily 
filled with dead cells and keratin which keep the skin waterproof. This layer sloughs off and allows newer 
cells to take their place. The dermis is composed of connective tissue and contains blood vessels, 
sebaceous glands and sweat glands. The sebaceous glands secrete sebum maintaining the pH of the skin at 
about 3 to 5, which inhibits the growth of many microorganisms. Importantly, the dermis also contains 
antigen presenting cells as described later. The mucous membranes act as protective shields by entrapping 
pathogens in the mucus fibers from entering the body.  
In addition to these anatomic barriers, an additional layer of protection is imparted by biological 
conditions such as temperature and pH.10 Some organisms cannot grow well at physiological temperature 
(37oC). The pH of the stomach is also instrumental in eliminating many of the microorganisms that we 
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ingest. Lysozyme, which is found in tears and saliva, is also useful in clearing harmful bacteria by causing 
damage to bacterial cell walls.  
Apart from these physical barriers, the innate immune system also protects against infections at 
the cellular levels by recruiting cells such as macrophages, dendritic cells, and neutrophils.10 
Macrophages are among the most common cells of the innate system. These cells are known as 
monocytes, when in an inactivated state. They travel around the body sampling their immediate vicinity, 
waiting to become activated. There are a number of ways a monocyte can get activated to become a 
macrophage. Phagocytosis of bacteria or the use of pattern recognition receptors are among the most 
common ways that a macrophage may become activated.  
Pattern recognition receptors (PRR’s) are among the most interesting molecules in the innate 
immune system. These serve as one of the connections between innate and acquired immunity.11,12 Our 
immune system has selected these molecules over millions of years of evolution to recognize molecules 
from potential pathogens. There are two types of PRR’s – soluble and cell associated receptors. An 
example of soluble PRR’s is C - reactive protein (CRP), which binds to several proteins on microbial 
membranes. These bound proteins then assist in activating complement and in recruiting macrophages to 
assist in phagocytosis of the microbe. Another example of soluble PRR’s is the MBL or mannose binding 
lectin, which binds to mannose containing carbohydrates on cell walls of bacteria. These proteins help in 
opsinization of the bacteria and in activation of complement. The other type of PRR is the cell associated 
receptors. The most famous example of this class of PRR’s are the toll-like receptors or TLRs. These 
represent a specific class of receptors that are associated with host immune cells, and may be present in 
either the interior or exterior of cells. There are 13 types of mammalian TLRs discovered so far.13 To 
name and describe a few, TLR-4 binds to LPS on bacterial cell walls, TLR-3 binds to double stranded 
RNA typically found in viruses and TLR-9 binds to CPG sequences on bacterial DNA. When the TLR 
binds its target, it activates the cell on which it is expressed. Many recently identified adjuvants work by 
binding to TLRs and activating the innate immune system.14   
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The complement system is also a part of the innate immune system, which is often recruited by 
the adaptive system to clear pathogens from the body.15,16 The complement system is made up of over 25 
different proteins. When activated, a cascade of a reactions take place involving these small proteins and 
ultimately ends with the formation of a “membrane attack complex” or MAC.17,18 This MAC forms a 
transmembrane channel in the pathogen, which leads to lysis of the target cell. Several different pathways 
have been identified leading to the activation of the complement system including the classical19, lectin 20 
and alternate pathway21. Additional information regarding the complement system may be obtained 
elsewhere. 11,16-19,21 
 Inflammatory response can be considered as another branch of the innate immune 
system.10 Inflammation is characterized by redness, swelling and pain. Activated macrophages secrete 
several important chemical factors into the extracellular space that promotes inflammation. For instance, 
macrophages secrete interleukin-1 which activates T-helper cells and also travels to the brain and induces 
a fever. The increased body temperature decreases pathogenic activity. C-reactive protein discussed on 
the previous page is a key biomarker for inflammation.  
The cells of the innate immune system such as macrophages and neutrophils are largely non-
specific and have no ability to perform self/non-self discrimination. They are, however, instrumental in 
activating the adaptive immune system. Macrophages and dendritic cells are largely responsible for 
processing and presenting antigen to cells of the adaptive immune system. Hence, these cells are also 
called antigen presenting cells (APCs). They present fragments of antigens on their major 
histocompatibility complex protein (MHC), for T-cells to recognize. MHCs are protein complexes that 
are expressed on almost all cells in the body and help the immune system differentiate between self and 
non-self entities.22 There are two types of MHC designated MHC-I and MHC-II. Almost all nucleated 
cells in the body express MHC-1 while only professional antigen presenting cells express MHC-II. When 
a cell is infected by a pathogen, it tries to digest the pathogen in the lysosomal compartment. Here, the 
proteins from the pathogen are digested by proteases and the resulting peptides are complexed with the 
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MHC receptor and trafficked to the surface of the cell for recognition by T cells. MHC-I can bind most 
effectively to peptides that are about 9 amino acids long while MHC-II can bind peptides 13-18 amino 
acids in length. Generally, MHC-1 displays peptides that are derived from endogenous pathogens while 
MHC-II displays proteins derived from exogenous microorganisms. A more detailed description of 
MHC’s, and their structure and function are described in depth elsewhere. 23-25 
The adaptive immune system contains a different set of cells that learn to recognize specific 
pathogens and effectively neutralize them.26 The best characterized cells of the adaptive immune system 
are the B and T-cells. B-cells are largely responsible for the humoral, antibody response, while the T-cells 
primarily constitute the cellular response. These two classes of cells, however, assist in activating each 
other in the various stages on the adaptive immune response. For instance, T-Helper cells are essential in 
activating the B-Cells which eventually produce specific antibodies against the pathogen.  
The antibody response is primarily the defense most vaccines today elicit. Table 2 lists some 
selected currently licensed vaccines along with the type of immune response they elicit.27 Most subunit 
and inactivated viral vaccines primarily elicit an antibody response. Some of the live attenuated viral 
vaccines, however, produce both CD8+ and CD4+ activity in addition to the antibody response.  B-cells 
mature in the bone marrow and express a unique antigen binding receptor on its surface.26 This membrane 
bound highly selective antigen binding receptor is called a membrane antibody. Each B-cell expresses 
about 10,000 antibody molecules on its surface and each of these antibodies has the same specificity 
towards a specific antigen and is identical to the other antibodies on the same cell. The entire population 
of B cells in the human body can make up to 108 different antibodies. A naïve B-cell expresses a receptor 
that has affinity towards one specific antigen. Upon binding to the antigen, the B-cell is activated and 
differentiates into B-memory and plasma cells. Plasma cells are able to secrete large quantities of 
antibody in to the extracellular space. Antibodies have two biological functions. One is to bind to the 
pathogen and the second is to facilitate effector functions. An antibody molecule is composed of 2 heavy 
and 2 light chains. There are 5 types of antibodies in the body and they differ based on the 5 different 
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heavy chains used to make up the antibody. These are IgA, IgD, IgM, IgG and IgE classes. More detailed 
descriptions of the structure of these antibodies may be found elsewhere.28  Once the antibodies bind to 
the pathogen, they signal macrophages and other immune cells for destruction of the pathogen by 
phagocytosis. Antibodies can also activate the complement system by the classical pathway, which then 
assists in the destruction of the pathogen or tumor. Additionally, antibodies can initiate a cellular response 
via antibody dependent cell-mediated cytotoxicity.  
T-cells mature in the thymus and exist in a number of different types. The most common types 
are the T-helper cells and the cytotoxic T cells.29,30 The T-helper (Th) cells have a CD4 receptor on their 
surface, which recognize peptides presented on MHC-II by APCs. This activates the Th cell, which then 
begins to proliferate and later develop into Th1 and Th2 cells. Th1 cells secrete cytokines to maximize the 
efficiency of macrophages and also activate other cytotoxic T cells, thereby assisting the cellular immune 
response.31 Th2 cells go on to play an active role in the activation of B-cells, thereby initiating the 
humoral response.  
The T cytotoxic cells (Tc) have a CD8 receptor on their surface, which recognizes peptides 
presented on MHC-I by all host cells.32 This activates the Tc cells to become cytotoxic T cells (CTLs), 
which can then kill infected or modified cells directly by the use of various agents such as perforin and 
granzymes. Alternatively, CTLs can also induce apoptosis in target cell by interaction with FAS 
receptors. T-regulatory or Treg cells play a key role in regulating the immune response. They help by 
lowering the immune response when not needed, as in the case of self-antigens.   
The hallmark of the adaptive immune system is the induction of memory.33 Memory is brought 
about by the differentiation of B-cells and T-cells during their activation into B and T memory cells. 
These cells can live and circulate in the body for decades after the primary infection. In case of a second 
infection, these memory cells become activated and quickly proliferate and raise the appropriate immune 
response to neutralize the invading pathogen. Vaccines work by inducing memory. For instance, 
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immunization with a live attenuated strain of a virus causes a minor form of infection. Some infected host 
cells release several cytokines to attract macrophages and other immune cells to the site of infection. 
These macrophages then begin to digest the cells and viruses, and degrade them. Within the next couple 
of hours, the viral proteins are degraded into peptides and presented to T-helper cells in their MHC-II 
compartment. The Th cells are then activated and assist in the activation of B cells which secrete 
antibodies that help to neutralize the virus. In parallel, the infected cells present viral peptides to Tc cells 
in their MHC-I compartment. This activates the Tc cells to become cytotoxic T cells which then help 
eliminate viral infected cells. During the activation of the B and T cells, the progenitor cells also 
differentiate into B and T memory cells. These cells tend to circulate in regions where the virus was first 
encountered and the lymph codes. Should they encounter the same antigen again, they proliferate rapidly 
and work to rapidly eliminate the pathogen for the body.  
Types of Vaccines  
 
 Modern vaccines come in several different types. Advances in technology and science have in a 
few cases enabled us to develop vaccines based on individual proteins from the pathogen.  Many vaccines 
available today are those that were developed using traditional methods. These vaccines can be broadly 
divided into two categories – Whole organism based vaccines and subunit vaccines.34-36 Whole organism 
vaccines employ attenuated or inactivated forms of a virus or bacteria that cause disease. Different 
strategies may be employed to achieve an attenuated strain of the disease causing agent. One approach is 
to use a similar viral strain that may be pathogenic in other animals but does not cause disease in humans. 
A classic example employs vaccinia which causes cowpox in humans, but protects humans from the more 
deadly smallpox without causing significant disease. Another example is the use of herpes virus from 
turkeys to control Marek disease in chickens. A second strategy attenuates a viral strain by mutating it by 
passaging the virus through cells obtained from another host. Examples of vaccines developed using this 
technique are the original rabies vaccine by Pasteur and the MMR vaccine against measles, mumps and 
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rubella.  A third strategy is the use of a naturally occurring attenuated strain to protect against disease 
from the harmful strains. A good example of this is the use of weaker strains in the polio vaccine.   
Traditional sub-unit vaccines are comprised of an inactivated form of a component of the 
pathogen as opposed to using the whole organism. In general, these are safer and have fewer side effects 
because they do not cause even mild disease. Examples of traditional sub-unit vaccines are the vaccines 
for tetanus and diphtheria. These bacteria are non-invasive, but the toxins they secrete can be deadly. 
These toxins can be “inactivated” by treatment with formalin or some other agent. These inactivated 
forms of the toxin, known as toxoids, can generate a neutralizing immune response against the toxin when 
injected into humans. Another example of a sub-unit vaccine is the split influenza vaccine. This vaccine is 
made by disrupting the virus by the use of various detergents and separating the two major surface 
antigens – haemagglutinin (HA) and neuraminidase (NA). The mixture of these two proteins is used in 
the seasonal flu vaccine. In some countries, an “adjuvant” is added to such vaccines to boost the immune 
response. 37,38 
Recombinant DNA technology has opened a number of possibilities in the area of vaccines.31,33 
Isolating and purifying a specific antigen from an infectious agent in large quantities has been a major 
challenge. This particular roadblock has now been overcome. It is now much easier to produce large 
quantities of pure antigen to enable their characterization and evaluation of their efficacy. With 
recombinant DNA technology, it has also become possible to insert a particular antigen in a suitable 
vector to increase the efficacy of the vaccine. A recombinant rabies vaccine (V-RG) for veterinary was 
developed by inserting a glycoprotein gene into the vaccinia virus.39 Similar techniques are being tried 
with various other antigens. Currently, significant efforts involve the development of individual protein 
antigens as vaccines. These recombinant sub-unit vaccines have a well-defined structure and are often 
more stable than their live attenuated counter parts. These sub-unit vaccines can also be manufactured in 
bulk more easily. They do, however, have some disadvantages. Most isolated proteins have low intrinsic 
immunogenicity and cannot be used as vaccines by themselves. They require additives that boost their 
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immunogenicity. These additives are called “adjuvants” and will be discussed in detail later in this 
chapter. The human papilloma vaccine employs “virus-like particles” assembled from the recombinantly 
produced coat proteins of the human papilloma virus. The human papilloma vaccine also contains 
aluminum oxyhydroxide or Alhydrogel as an adjuvant to boost its immune response. A similar approach 
is used in the recombinant hepatitis B vaccines. DNA vaccines are relatively a new concept. This involves 
the use of a plasmid encoding a particular antigen as the vaccine. When cells start to take up such DNA, 
they can express the antigens with a resultant immune response. Significant interest has been spurred in 
this area because nucleic acid-based vaccines are able to elicit both a cellular response and humoral 
immune response. Most vaccines today, with the exception of live viruses elicit primarily a humoral 
response. Problematically, however, the cellular response is thought to be key in the development of 
vaccines towards TB, HIV and malaria among other diseases. 
Discovery and Development of Vaccines 
 
To develop more effective vaccines in the future, improvements can be made in at least two areas 
of vaccines development. One area deals with the identification of novel targets as vaccines candidates. 
The other concerns formulation and delivery aspects of vaccine development. Both of these areas have 
witnessed several breakthroughs in the past few decades. A brief introduction to some of the new methods 
used to identify vaccine targets is discussed below. The remainder of this chapter will be dedicated to the 
use of formulation to increase vaccine stability and efficacy.  
Traditionally, vaccines candidates were discovered on a trial and error basis. Some were 
discovered before science even knew of the existence of viruses. For instance, the small pox and rabies 
vaccines created by Pasteur were developed before the microbial basis of disease was widely accepted.7 
Most of the vaccines used today were developed using traditional vaccinology technologies. Several of 
these were developed by inactivating or attenuating the pathogens, or in some cases, isolating the 
antigenic subunits. These approaches have been very successful in the past and have helped save tons of 
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millions of lives. There are, however, several examples where such techniques have failed due to safety 
concerns and low efficacy. Attenuated vaccines may revert back to virulent states and cause full blown 
disease in those vaccinated. Killed and attenuated whole organism vaccines may share protein sequence 
homology with human proteins, which may cause autoimmune disease. Identifying immunogenic 
subunits by classical methods is time consuming and often difficult.  Today, antigen discovery is broadly 
based around two predictive methods. One is called Reverse Vaccinology and the other Antigenome 
technology. 40,41 
Reverse vaccinology uses bioinformatic analysis of the infectious agent’s genome to select 
possible antigens. As multiple genomes of most human pathogens are now available in databases online, 
the initial information required to predict the first batch of vaccine candidates is freely available. This 
data is subjected to various predictive methods (bioinformatics, comparative genomics, proteomics, and 
DNA microarray analysis) to obtain a number of antigens that can be used in animal models to determine 
which are the most immunogenic. These initial predictive methods are primarily based on in silico 
analysis of the host genome. Additional methods are, however, constantly being implemented. The two 
most commonly used predictive methods are DNA sequence similarity searches such as FASTA or Psi-
BLAST and protein location predictive algorithms such as PSort, SignalP or TMPRED. These algorithms 
provide us with similar, previously studied surface proteins that may be tested as antigens against the 
specific pathogen. Any “hits” obtained here are further refined with additional algorithm. The results from 
this part of the study are then studied in animal models to determine which antigens are the most 
immunogenic. One example of a potential vaccine created by this method is the multivalent recombinant 
MenB vaccine that is in phase III clinical trials. The Antigenome technology is a relatively newer. This 
technology combines the advantages of full pathogen genome coverage with serological antigen 
identification. The antigens characterized and formulated in Chapter 3 were discovered using Antigenome 
technology.  
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Adjuvants 
 
 The discovery of vaccine candidates is only the start of any vaccine development program. A 
whole new set of problems are usually encountered when one tries to make an actual vaccine from a 
specific antigen. These problems can broadly be classified into efficacy and stability problems. Most 
subunit vaccines are not highly immunogenic by themselves compared to their whole cell counterparts. 
To induce a robust immune response, multiple injections of the vaccine are often required and in many 
cases, the addition of an adjuvant is needed to increase the immunogenicity of the vaccine.37,38 An 
adjuvant is a substance that can increase the immunogenicity of the antigen, but they do not confer 
immunity by themselves. The most commonly currently used adjuvants are the aluminum salts – 
aluminum oxyhydroxide (aluminum hydroxide) and aluminum hydroxyphosphate (aluminum phosphate). 
These were the first and only adjuvant to be approved for use in the United States until very recently. 
These adjuvants are known for their ability to induce a robust antibody response. Over the last half a 
century, hundreds of millions of doses of vaccines containing aluminum salt adjuvants have been 
administered. These adjuvants thus have an established safety and efficacy profile. These adjuvants are 
typically made by the precipitation of aluminum when a solution of alum (aluminum potassium sulfate) is 
titrated with a base such as ammonium hydroxide or sodium hydroxide.42 The distinction between 
Alhydrogel and Adjuphos is in the degree of phosphate substitution for hydroxyl groups on the surface of 
the adjuvant.38,43 This substitution imparts differences in surface charge leading to differential adsorption 
of antigens to the surface. This adsorption of the antigen to the surface of the adjuvant is thought to be 
required for the increase in immunogenicity imparted by the adjuvant, although this view has recently 
been challenged.44 The major forces responsible for the adsorption of the antigen to the adjuvant are 
electrostatic interactions, hydrophobic forces and ligand exchange. Generally, since proteins and 
aluminum salt adjuvants are charged, electrostatic interactions often seem to be the major mechanism for 
adsorption of proteins to the adjuvant surface. At neutral pH, Alhydrogel (pI=11.4) is usually positively 
charged and Adjuphos (pI=4.5 to 5.5) is negatively charged. It is possible to optimize these interactions 
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by modifying formulation parameters such as pH, ionic strength and the addition of ions such as 
phosphate, and sulfate.  
 The adjuvanticity of the aluminum salts is characterized by an antibody response by the T helper 
type 2 cells as stated earlier. There are several proposed mechanisms of immunopotentiation by aluminum 
salt adjuvants.45  The depot theory postulates that the aluminum adjuvant and the adsorbed antigen remain 
at the site of injection.42 The slow release of antigen from the adjuvant stimulates antibody production. 
38Another theory predicts that the adjuvants cause inflammation at the site of injection, attracting antigen 
presenting cells (APC’s) in large numbers. The APCs encounter the antigen at high concentration, thereby 
facilitating an immune response against it. Yet another theory postulates that there may be particulation of 
antigen on the surface of the adjuvant, which end up being internalized by macrophages via phagocytosis 
leading to an immune response. Recently it was proposed that the immune response may be raised by 
dendritic cells (DCs) and re-assortment of the DCs’ lipid membrane upon interaction with the adjuvant.46 
This interactions leads to antigen being delivered in its soluble form to the dendritic cell, which is then 
processed in its MHC class II compartment which results in the activation of B-cells to raise an antibody 
response. It is possible that all of these mechanisms contribute to immunopotentiation by these adjuvants.  
 Adsorption of the antigen to the surface of the adjuvant has been shown to sometimes induce 
changes in the secondary and tertiary structure of the antigen and frequently to reduce their thermal 
stability.47-49 This destabilization of the antigen has also been suggested as one of the causes for the 
adjuvanticity of aluminum salts since APCs are able to better degrade destabilized proteins.47 The depot 
theory had originally led to the belief that adsorption of the antigen to the adjuvant was necessary for a 
robust immune response. This view has, however, been challenged in the recent years and there are a 
number of examples where the contrary appears to be true.44 The importance of adsorption may be 
antigen specific and additional studies will need to be done in the future to clarify this. Current regulatory 
guidelines do, however, define a need for adsorption of the antigen as a general rule of thumb. The dose 
of adjuvant can also play an important role in the immunogenicity of the vaccine. Limits for the amount 
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of aluminum adjuvants in vaccines in injectibles are 1.25mg of aluminum per dose if the manufacturer 
can justify the need for the high concentration with safety and efficacy data (Code of Federal Regulations, 
2003). Typically, most vaccines tend to contain less than 0.85mg of aluminum per dose. Table 3 lists 
select currently marketed vaccines that contain aluminum salt adjuvants along with their doses.38  
 Recently, with the release of Cervarix ®, AS04 was the second adjuvant to be licensed in the 
United States.50 AS04 consists of monophosphoryl lipid A (MPL) adsorbed to aluminum hydroxide. MPL 
is a TLR4 agonist and is derived from the cell wall of gram-negative salmonella. This is detoxified by 
hydrolytic treatment and purified. AS04 is used as an adjuvant in the human pappilomavirus vaccine 
developed by GSK. In Europe, MF59 is the only other adjuvant that is approved for human use.51 MF59 
is an oil-in-water emulsion containing squalene. The squalene droplets are stabilized in water by the used 
of two surfactacts – tween-80 and sorbitan trioleate. MF-59 is used in the influenza vaccine, Fluad™. 
Some studies have indicated that the addition of MF59 as an adjuvant may provide a broader serological 
response than aluminum salt adjuvants. There are several other adjuvants used for veterinary purposes 
such as Freunds complete and incomplete adjuvants. The use of these adjuvants in humans, however, is 
unacceptable due to their toxicity.38  Today, greater emphasis is being placed on the discovery and 
development of novel adjuvants to elicit robust cellular and antibody responses in both new and older 
vaccines.  
 Aluminum salt adjuvants will probably remain one of the most commonly used adjuvants in 
vaccines worldwide.38,43,52 These adjuvants have a safety profile established over half a century and 
millions of doses. The transitions to newer adjuvants in vaccines require changes in regulatory policies 
and this has met with limited success.  
Vaccine Stability 
 
 An antigen that can elicit an immune response towards its actual pathogen is the most common 
component of any vaccine. For instance, a live attenuated viral vaccine contains attenuated viral strains 
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while a sub-unit vaccine typically contains individual proteins or carbohydrates. In some cases, an 
adjuvant is added to boost the immune response as discussed earlier. The vaccines are, however, exposed 
to several environmental factors before being administered to patients. These include changes in 
temperature, exposure to light and physical stresses like shaking or stirring while being shipped. These 
factors may affect the stability of the antigen or the adjuvant and render them ineffective.53 For instance, 
freezing of aluminum adjuvants causes coagulation of the salt. The resulting mixture cannot be readily re-
dispersed upon thawing.54 Changes in temperature can also inactivate viruses and causes changes in the 
secondary, tertiary and quaternary levels of constituent proteins. Apart from conformational changes, 
aggregation of viruses and purified protein are also a common concern. By studying the physical and 
chemical stability of the antigen, we can characterize the origin of instability in these antigens and take 
necessary measures to minimize degradation. The most common way this is done is by the addition of 
stabilizers.55  
 Proteins have several levels of structure. The primary structure is defined as the amino acid 
sequence. This linear chain of amino acids can then interact with itself causing the protein to fold in 
various shapes and sizes to give rise to the secondary and tertiary levels of structure in a protein. Local 
interactions give rise to the secondary structure in terms of helices and sheets while the details of the 3D 
structure constitute its tertiary structure. These individual protein units or monomers can interact with 
other individual protein units to form dimers and higher oligomers to give rise to quaternary structure. For 
instance, an antibody is made up of 4 sub-units. Two heavy chain molecules and two light chain 
molecules come together to form an antibody.56 In this case, the monomers are held together by covalent 
(disulfide) bonds but it is often the case that the interactions between subunits are non-covalent in nature. 
All these levels of structure can be affected by environmental factors such as pH, temperature and ionic 
strength.53,57-59 For example, the charge state of individual amino acids is dictated by the pH of its 
environment, which in turn effects their contributions to the various levels of structure in a protein. Ionic 
strength can weaken the electrostatic interactions while high salt concentrations can increase the strength 
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of apolar interactions. In vaccine development, ionic strength can also weaken interactions between the 
antigen and the adjuvant, which may be crucial for immunogenicity. Increases in temperature can weaken 
bonds stabilizing the protein which may cause irreversible unfolding of the protein. This unfolding may 
expose hydrophobic regions which can then interact with one another causing protein aggregation.  These 
factors may also be involved in chemical degradation of the protein. For instance, deamidation of the 
asparagine residues in the protein can be stimulated at both high and low pH resulting in the formation of 
aspartic or iso-aspartic acid. Any of these factors may contribute to protein instability and loss in 
immunogenicity.53,60 It is, therefore, very important to characterize a protein antigen to the fullest possible 
extent to enable selection of suitable formulation criteria to maintain the immunogenicity of the vaccine 
from manufacturing to administration. It is important to note that vaccines are shipped all over the world. 
They are desperately needed in the remote sites of the developing world where access to refrigerators may 
be limited. Effective formulations should ideally be able to keep the vaccines stable even at room 
temperatures in these cases. Unfortunately, this is currently not often the case.  
 The structural aspects of proteins are best defined by high resolution methods such as X-ray 
crystallography and NMR. These methods are, however, time consuming, and utilize large amounts of 
protein (which may not be available in the early stages of vaccine development). Therefore, low 
resolution methods such as circular dichroism (CD), fourier transform infrared (FTIR), ultraviolet (UV) 
absorbance and fluorescence spectroscopy and light scattering, and differential scanning calorimetry 
(DSC) are usually employed. Changes in data from such methods as a function of environmental stresses 
such as pH and temperature are useful in producing an information-rich stability profile for a biological 
entity as a function of the stresses applied. CD and FTIR spectroscopy can be used to study changes in the 
secondary structure of the protein, and intrinsic and extrinsic fluorescence spectroscopy as well as near 
UV CD and near UV absorption spectroscopy can be used to study the changes associated with tertiary 
structure. Aggregation events can be monitored using static and dynamic light scattering, size exclusion 
chromatography and a wide variety of other methods.  
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 The use of these structural assays in combination can provide an overall picture of a protein’s 
stability as a function of environmental stress.  This can provide an idea of the most favorable and optimal 
conditions for a target protein. It also enables one to screen for suitable stabilizers that may enhance the 
stability of the protein. The most commonly used stabilizers are sugars, sugar alcohols, amino acids and 
surfactants.61-63 Sugars and sugar alcohols such as sucrose and sorbitol stabilize proteins by preferential 
hydration.63 Surfactants such a polysorbate-20 stabilize proteins by various non-specific interactions. For 
example, they coat hydrophobic surfaces such as the walls of a container and the air-water interface 
preventing protein adsorption and ultimately, aggregation of the protein.  
 Apart from the addition of stabilizers, other techniques may be used to slow or prevent protein 
degradation. The most common method is lyophilization (freeze drying) of the protein.64-66 This technique 
involves removing most of the water in the formulation. Biological entities such as proteins and viruses 
usually exhibit enhanced stability in the dried state due to the reduction in reactive water as well as their 
internal motions. Though not common, protein sub-unit vaccines may sometimes be stabilized upon 
adsorption to adjuvants. In a molecular design approach, unstable regions of the proteins may be removed 
or certain amino acids replaced to further stabilize the antigen.   
 In addition, preservatives may be added to vaccine formulations to prevent the growth of other 
microorganisms.67 Improvements in sterile manufacturing technologies over the last few decades have 
greatly reduced the need for preservatives in vaccines. Regulatory policies require manufacturers to 
include preservatives in multi-dose vials. Care should be taken to determine that these preservatives do 
not destabilize or degrade the antigen. There are four commonly used preservatives in vaccines. They are 
phenol, thimerosal, benzethonium chloride and 2-phenoxy-ethanol.  The addition of thimerosal produced 
considerable controversy. Thimerosal was casually linked to the development of autism in children, 
despite the lack of any supportive scientific data. An in-depth and thorough study of the link between 
autism and thimerosal found no relationship between the two and the hypothesis has been definitely 
refuted.   
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 Apart from the addition of adjuvants, stabilizers and preservatives, viral or subunit vaccines may 
also contain trace amounts of chemicals used to inactivate the viral or the toxin components.67 The most 
commonly used chemicals used for this purpose are formaldehyde, formalin and β–propiolactone. In 
addition, some manufacturing and cell culture residuals may also be present in a final vaccine formulation 
in trace quantities.  
 In the course of this dissertation, I dedicate each chapter to the formulation development of three 
unique vaccines. Central to the formulation development of each of the vaccines are biophysical 
characterization of the different biological entities. The data obtained from the various techniques 
discussed above were incorporated into an empirical phase diagram (EPD), a form of stress-response 
diagram that will be described later. This was done to visualize pH and temperature ranges over which the 
antigens were most stable. This empirical phase diagram approach has been used before to successfully 
characterize several proteins.68-77 After constructing an EPD for each of the antigens, an assay was 
developed to screen for potential stabilizers. Finally, the antigens were formulated with an adjuvant when 
required. The interactions between the antigen and the adjuvant were fully characterized and the stability 
of the antigen on the adjuvant surface was assessed by various spectroscopic methods. Chapter 2 deals 
with developing a stable formulation for a recombinantly produced hemagglutinin protein (HAC1) in the 
presence of Alhydrogel. This is intended for use a vaccine towards seasonal flu. The immunogenicity of 
HAC1 was tested in mice in the presence and absence of Alhydrogel. Phase I clinical trials for this 
vaccine was recently successfully completed and Phase II is currently underway. Chapter 3 outlines the 
formulation development of a recombinantly produced trivalent subunit protein vaccine against S. 
Pneumonia. The antigens used in this study were discovered using the Antigenome technology discussed 
earlier. Chapter 4 describes the development of a formulation for a trivalent live attenuated viral vaccine 
for dogs. The last chapter provides some conclusions and a summary of the work described in this 
dissertation.  
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Introduction 
	  
Influenza is one of the leading causes of respiratory infections worldwide and is 
associated with significant morbidity and mortality each year. There are several subtypes of the 
influenza virus that are currently circulating among humans.1,2 An effective way to combat 
influenza is through vaccination using a trivalent vaccine produced in embryonated chicken 
eggs. Almost all commercially available vaccines contain two surface glycoproteins of influenza, 
hemagglutinin (HA) and neuraminidase (NA), as the key antigens, with HA being the dominant 
one of the two. Although this system has worked well over the past five decades, it has several 
well-recognized disadvantages.1 One of the major disadvantages of this costly and time-
consuming egg-based technology is that it is difficult to respond to a potential pandemic crisis in 
a timely manner, since a minimum of 3-6 months is required to generate an influenza vaccine.2-5  
The H1N1/09 virus was responsible for the 2009 swine flu epidemic. Significant morbidity and 
mortality associated with this disease were due to the lack of an effective vaccine.6 More than 
506,060 cases of the H1N1/09 infections have been reported worldwide, with over 6770 deaths.7 
These numbers may have been significantly underestimated, since it is no longer required to 
report all clinically diagnosed cases.  
 To prevent or effectively diminish the impact of influenza, it is imperative to have a 
system that can rapidly produce the vaccine when needed. Two relatively new technologies 
which are being tested to replace the egg-based production system are cell culture-based and 
recombinant protein (antigen)-based approaches.5,8-11 The cell culture-based technology has its 
own limitations since the process still requires the production of re-assorted virus similarly to the 
egg-based technology12,13 and has a number of other safety-associated concerns.5 In contrast, the 
recombinant protein-based approach involves the use of purified viral surface antigens (HA 
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and/or NA) as the active component of the vaccine. HA is recognized as the key antigen in the 
host response induced by influenza vaccination and thus is a logical candidate for a recombinant 
influenza vaccine. Currently, there are no commercially available recombinant influenza 
vaccines, although many are in development, including purified HA-based as well as virus-like 
particle (VLP)-based vaccines.5,8-11  
The currently available systems for the commercial production of recombinant protein 
vaccines include bacteria, yeast, insect and mammalian cell cultures. Although each of these 
systems has specific advantages, their application and use are limited due to insufficient 
scalability, safety concerns, high cost and target integrity. A much cheaper, safer and highly 
scalable alternative for recombinant subunit vaccine production is a plant-based system that can 
generate proteins in their native form with the desired properties.14 A number of human and 
animal recombinant subunit vaccines have been produced in plants to date and have been 
demonstrated to be efficacious and safe in preclinical and clinical studies.14,15  
In this report, we have conducted studies to formulate a recombinant HA protein (HAC1) 
from H1N1 influenza A (A/California/04/09 strain) produced in Nicotiana benthamiana plants as 
an early developmental step towards the generation of a commercially viable vaccine.  In this 
work, we also test the utility of accelerated stability studies.  
Materials and Methods  
	  
 Plant-derived HA, HAC1, was produced by Fraunhofer CMB Inc. (Newark, DE)16 and 
supplied as a frozen solution. For initial characterization studies, citrate phosphate (CP) buffers 
(20 mM, pH 3.0-8.0) with an ionic strength of 0.15 (adjusted with NaCl) were used.  Imidazole 
buffer (10 mM, pH 7.0) containing 150 mM NaCl was used for excipient screening and adjuvant 
studies. For buffer exchange, protein was dialyzed at 4 °C using Slide-A-Lyzer® Dialysis 
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Cassettes, 10 kDa MWCO (Pierce, Rockford, IL). Alhydrogel® (2%) was obtained from 
Brenntag Biosector, Frederickssund, Denmark. All other reagents were of analytical grade. 
Protein concentration was determined by UV absorbance at 280 nm using an extinction 
coefficient of 1.36 ml/mg-cm for HAC1. Experiments in the presence of the adjuvant were 
conducted by adding Alhydrogel® to the protein (or the protein-excipient mixture). 
Characterization of the physical stability of HAC1  
Sample preparation 
	  
  For each of the spectroscopic techniques, duplicate samples were prepared at different pH 
values (pH 3.0 to 8.0, at one pH unit intervals) by dilution of the stock material with 20 mM CP 
buffer of the appropriate pH. The ionic strength of each sample was kept constant at a value of 
0.15 using NaCl. Protein solutions were studied at a concentration of 0.2 mg/ml for CD studies 
and 0.1 mg/ml for fluorescence studies. 
Far-UV circular dichroism (CD) spectroscopy 
	  
 CD spectra were acquired using a Jasco J-810 spectropolarimeter equipped with a 6-
position peltier temperature-controlled sample cell holder (Jasco Inc., Easton, MD). The CD 
spectra were recorded from 260-190 nm with a scanning speed of 50 nm/min, a response time of 
2 second and an accumulation of 3.To study thermal transitions (melting curves) of the proteins 
(in sealed cuvettes of 0.1 cm pathlength), the CD signal at 222 nm was monitored every 2.5 °C 
with a 3 minute equilibration over a 10 to 87.5 °C temperature range employing a temperature 
ramp of 15 °C/hr. A buffer baseline was subtracted from each spectrum. 
Intrinsic tryptophan (Trp) fluorescence spectroscopy 
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 Fluorescence spectra were acquired using a Photon Technology International (PTI) 
spectrofluorometer (Lawrenceville, NJ) equipped with a turreted 4-position peltier-controlled 
cell holder. An excitation wavelength of 295 nm was used to excite Trp residues and the 
emission spectra (>95% Trp emission) were collected from 310 to 400 nm. Light scattering was 
monitored using a second detector located at 180° to the emission detector, and was collected at 
295 nm. Emission spectra were collected every 2.5 °C with a 3 minute equilibration period at 
each temperature over the temperature range of 10 to 87.5 °C in a 1 cm pathlength quartz 
cuvette. A buffer baseline was subtracted from each raw emission spectrum. Peak positions and 
intensities of the emission spectra were obtained using a mean spectral center of mass (MSM) 
method which increases the actual peak positions by about 8-10 nm, but yields a better signal to 
noise ratio and increased reproducibility. 
ANS fluorescence spectroscopy 
	  
 The accessibility of apolar sites on protein surfaces was monitored by fluorescence 
emission of the extrinsic probe 8-anilino-1-naphthalene sulfonate (ANS). Each sample contained 
an optimized 15-fold molar excess of ANS to protein. The ANS was excited at 375 nm and 
emission spectra were collected from 400-600 nm. Emission spectra were collected every 2.5 °C 
with a 3 min equilibration period over a temperature range of 10 to 87.5 °C. The ANS-buffer 
baseline at each corresponding pH was subtracted from raw emission spectra. Peak intensities of 
the emission spectra were obtained using the MSM method.  
Empirical phase diagrams (EPDs) 
	  
 EPDs were constructed as previously described.17 CD molar ellipticity at 222 nm, 
intrinsic Trp fluorescence peak intensity and peak shift, light scattering intensity and ANS 
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fluorescence peak intensity data sets were used for construction of the empirical phase diagram. 
All calculations were performed using Matlab software (The MathWorks, Natick, MA). Briefly, 
the experimental data sets were represented as n-dimensional vectors in n x n density matrices, 
where n is the number of variables (e.g. CD, fluorescence, light scattering, etc.) at each pH-
temperature combination. The density matrices were used to derive n sets of eigenvalues and 
eigenvectors. The three eigenvectors which corresponded to the highest eigenvalues were 
employed to re-expand the data into three dimensions, and each vector was assigned a color (red, 
green or blue). The resulting multi-colored plot represents contributions of each vector at a given 
pH/temperature value. Thus, regions of the plot with similar color indicate similar physical states 
of the protein. A detailed explanation of the calculations involved in construction of EPDs is 
presented elsewhere.18,19 
Excipient screening  
	  
 Prior to excipient screening, an accelerated stability assay based on intrinsic fluorescence 
and light scattering (using thermal transitions) was employed to select an optimal buffer system 
at pH 7.0. After observing insignificant differences in protein stability in the buffers tested 
including PBS, imidazole and citrate-phosphate, imidazole was chosen as the buffer for further 
experiments. For excipient screening, duplicate samples were prepared at pH 7.0 in 10 mM 
imidazole buffer. The ionic strength of all samples was kept constant at a value of 0.15 using 
NaCl. Protein solutions were studied at a concentration of 0.1 mg/ml for these studies. The 
intrinsic fluorescence assay was further used to screen for stabilizing compounds. Thermal 
transition plots of the protein in the presence of various GRAS (Generally Regarded as Safe) 
excipients were acquired using the PTI spectrofluorometer as described above.  The excipients 
that shift the thermal transitions to higher temperatures are defined as stabilizers, while those that 
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shift the curves towards lower temperatures are considered destabilizers. Thus, the extent of 
stabilization and delay in aggregation of protein by the excipients were evaluated by their ability 
to shift the midpoint of the thermal transition temperature (Tm) of the protein to higher 
temperatures. The Tm values were obtained by normalizing the melting curve between 0 and 100 
percent, i.e. the part of the curve before the transition initiates was set to 0, and the part of the 
curve after the transition is completed was set to 100. The temperature at which the melting 
curve crosses the 50% mark is then defined as the Tm. 
 Following identification of potential stabilizers, the concentration of the stabilizers was 
optimized. Once suitable concentrations of stabilizing compounds were obtained, the stabilizers 
were used in combinations to determine if any additive or synergistic effects could be obtained 
for stabilization of HAC1.  
Adjuvant binding and stability studies 
	  
The adsorptive capacity of HAC1 in the presence of Alhydrogel® at various 
concentrations (0.04 – 0.36 mg/ml at 0.04 unit intervals) was determined by constructing a 
binding isotherm. The protein solutions in the presence of 0.2 mg/ml Alhydrogel® were tumbled 
in an end-over-end tube rotator at 4 °C for 20 minutes in imidazole buffer at pH 7.0. The samples 
were centrifuged using an IEC Micromax centrifuge at 2,500 x g for 1 minute to pellet the 
adjuvant. The amount of protein remaining in the supernatants (measured by UV absorbance 
spectroscopy) was used for the construction of binding curves. The ability of the protein to bind 
to Alhydrogel® in the presence of excipients was determined by the same procedure. In this case, 
Alhydrogel® was added to the protein-excipient solution. 
Desorption of the protein from Alhydrogel® was monitored in the presence of several 
potential desorption agents including NaCl, guanidine hydrochloride, urea and sodium citrate. 
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The protein-Alhydrogel® pellets were prepared as described above. The pellets were washed 
with imidazole buffer (pH 7.0) to remove any protein present in the supernatant prior to addition 
of the desorption solution. The Alhydrogel® solutions were then tumbled in an end-over-end tube 
rotator at 4 °C for 20 minutes. The samples were centrifuged at 2,500 x g for 2 minutes to pellet 
the adjuvant. The amount of protein in the supernatant was used to measure the protein desorbed 
from the surface of the adjuvant. 
The thermal stability of the protein bound to Alhydrogel® was monitored by intrinsic Trp 
fluorescence spectroscopy. Protein (180 µg/ml) was added to Alhydrogel® (0.5 mg/ml) by the 
procedure described above, which ensured >90% bound protein. The solution was transferred 
into a 1 mm cuvette and the adjuvant was allowed to settle for 4 hours. The use of a small 
pathlength cuvette enables us to obtain the fluorescence spectra of the protein while adsorbed to 
the adjuvant.20 The pellet was then analyzed between 10 and 87.5 °C. The Tm values were 
obtained from the melting curves by intrinsic fluorescence spectroscopy. The effect of excipients 
on the stability on the adjuvant-bound protein was also tested. When tested with excipients, the 
adjuvant was always added last to the protein-excipient mixture.  
A heat treatment (“annealing”) of the protein was undertaken to see if this procedure 
offered any additional stability. Samples of the protein in the presence of the adjuvant were 
heated at 40, 50, or 60 °C for 10 minutes or 2 hours in a water bath. After the specified amount of 
time, they were allowed to cool to room temperature and then refrigerated at 4 °C until further 
experiments. The stability of the bound protein was tested as described above using intrinsic 
fluorescence spectroscopy. The stability of the annealed protein was studied in the presence of 
selected excipients as well.  
Immunogenicity of selected formulations of HAC1 in mice 
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 Immunogenicity of selected formulations of HAC1 was evaluated in mice using HAI 
antibody response as a parameter. Groups of 6-week–old Balb/c mice, 5 mice per group, were 
immunized with 18 µg/dose of HAC1 intramuscularly (i.m.) at 3-week intervals on study days 0 
and 21. The HAC1 formulations tested were prepared in the buffer containing 10 mM imidazole 
and 150 mM NaCl, pH 7, and included three formulations without Alhydrogel®, two formulations 
with Alhydrogel® (0.5 mg/ml of aluminum), and heat-treated (“annealed”) HAC1 with 
Alhydrogel® (to evaluate the effect of the heat treatment on the immunogenicity), as shown in 
Table 3. Animals in group 7 received HAC1 in saline with Alhydrogel® (1.8 mg/ml of aluminum), 
which has been previously shown to elicit robust HAI antibody responses in mice,16 and group 8 
received saline alone with 1.8 mg/ml of Alhydrogel® (a negative control group). Serum samples 
were collected prior to each immunization and at 2, 3 and 7 weeks after the second dose. Serum 
samples collected from immunized animals were first treated with a receptor-destroying enzyme 
(RDE; Denka Seiken Co. Ltd., Tokyo, Japan) and then tested in the HAI assay. The HAI assay was 
carried out using 0.75% turkey erythrocytes as described previously21, with an initial serum 
dilution of 1:20 against the A/California/07/09 x 179A virus (CDC # 2009713114). Immunized 
animals with HAI antibody titers of ≥1:40 were defined as seropositive. 
 Statistical analysis of data was performed using a two-tailed F-test with equal variance and 
significance was considered at a p value <0.05. Mouse serum samples without detectable HAI 
were assigned a value of 10.  
Results 
	  
Biophysical characterization of HAC1  
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 The CD spectrum of HAC1 at pH 7.0 and 10 °C displays a broad negative peak between 
205-225 nm with apparent double minima near 208 and 220 nm, indicating significant 
contributions from α-helices to the secondary structure of the protein (Figure 2.1). The CD 
spectrum at pH 7.0 is representative of what is seen at pH of 3.0-8.0 as well. The broad peak and 
significant negative ellipiticity at 215 nm, however, indicates the presence of some β-sheet as 
well. Decreases in the molar ellipiticity at 222 nm provide evidence for the loss of the α-helical 
secondary structure upon thermal stress (Figure 2.2). Only gradual transitions were evident at pH 
3.0, 4.0, and 5.0, which initiate at relatively low temperatures (~ 20-30 °C) (Figure 2.2A-C). A 
small transition is seen near 30 °C at pH 6.0 (Figure 2.2D). In contrast, much sharper transitions 
are observed at pH 7.0 and 8.0 at 45-50 °C (Figure 2.2E-F).  
Red shifts in protein Trp peak positions occur as buried Trp residues become exposed to 
a more polar environment and provide evidence for changes in the tertiary structure. Again, no 
sharp transitions are seen at pH 3.0, 4.0, and 5.0 (Figure 2.3). Instead, a very gradual shift is 
observed at these three pH values with peak positions at about 344 nm at 10 °C (note that the 
actual peak positions are ~ 10 nm lower). Sharp transitions are seen at pH 7.0 and 8.0 at about 50 
°C, with the peak position at about 340 nm at 10 °C.  At pH 6.0, the protein manifests a lower 
thermal stability compared to pH 7.0 and 8.0, with the peak position slightly red shifted to about 
342 nm at 10 °C and transitions initiating above 30 °C. 
Monitoring static light scattering intensity provides insight into the aggregation behavior 
of proteins in solution. Despite the absence of visible aggregates even after heating to 90 °C, the 
increasing static light intensity and corresponding transitions observed for HAC1 indicate 
formation of lower order aggregates with increases in temperature. At pH 3.0, 7.0, and 8.0, the 
aggregation transitions occur between 40-45 °C (Figure 2.4). At pH 6.0, the light scattering 
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intensity gradually increases without a sharp transition. The constant and low light scattering 
intensity throughout the entire temperature scan at pH 4.0 and 5.0 suggests that there is no 
detectable aggregate formation at these pH values.   
At pH 3.0-5.0, ANS shows significant fluorescence intensity at low temperatures 
suggesting that the tertiary structure of HAC1 is already structurally altered (see Figure 2.5). A 
gradual decrease in ANS fluorescence intensity is observed at these pH values indicating release 
of ANS from the protein as it further unfolds and/or increasing fluorescence quenching at higher 
temperatures. The transition at pH 6.0 starts at 42 °C, while the transitions at pH 7.0 and 8.0 
begin at higher temperature (52 °C) suggesting an increased conformational stability of HAC1 
around neutral pH, similar to that observed by the other techniques. Again, the protein at pH 6.0 
exhibits relatively increased stability compared to pH 3.0-5.0, but to a lesser extent than that seen 
at pH 7.0 and 8.0 as suggested by all of the biophysical studies.  
An empirical phase diagram (EPD) was created by combining the data shown above to 
reflect secondary and tertiary structural changes, aggregation state, and the accessibility of apolar 
binding sites in the protein as a function of pH and temperature (Figure 2.6). The blue region at 
the lower, right-hand corner of the diagram encompassing pH 7.0 and 8.0 and temperatures 
below 50 °C can be considered the region in which the protein is found to be in its native 
conformation (region I). Intrinsic fluorescence, ANS fluorescence and light scattering data all 
confirm this observation. Region II represents an intermediate state of the protein at pH 6.0 and 
temperatures below 40 °C. Regions V and VI, present at pH 6.0, 7.0 and 8.0 at elevated 
temperatures, represent a physical state in which the protein is severely structurally altered and 
aggregated. Region III (green), present at pH 3.0-5.0 and below 50-60 °C, represents a state of 
the protein that is partially structurally altered, but remains in a non-aggregated state. As the 
34	  
	  
temperature is increased above 50 °C at pH 3.0-5.0, additional behavior (greenish blue) is 
apparent. At pH 3.0, this reflects a transition observed in the static light scattering plots and 
represents a severely disrupted and aggregated state of the protein. At pH 4.0 and 5.0, this region 
represents a severely structurally altered state as indicated by CD and fluorescence data but lacks 
the presence of aggregates. 
Excipient screening 
	  
 Based on the EPD and thermal melts generated from data acquired during biophysical 
characterization of HAC1, pH 7.0 was selected for excipient screening based on the optimal 
conformational stability and aggregation profile of HAC1 at this pH. A series of GRAS 
compounds from a library previously found to be of wide utility were screened by fluorescence 
spectroscopy for their ability to enhance HAC1 conformational stability and prevent aggregation. 
Among those compounds evaluated in the screening were a variety of carbohydrates, nonionic 
surfactants, amino acids, polyalcohols and cyclodextrins (Table 2.1). Examples of the relative 
shifts in the thermal unfolding curves of HAC1 in the presence of excipients are shown in Figure 
2.7. The effect of excipients on the aggregation and conformational stability of HAC1 in 
imidazole buffer at pH 7.0 is summarized in Table 2.1 in the form of Tm values. Table 2.2 
summarizes the effect of concentration of selected stabilizing excipients on both the aggregation 
and conformational stability of HAC1. The potential stabilizers identified include dextrose, 
sorbitol, glycerol, and Tween-80. As seen in Table 2.1, 20% sorbitol, 20% dextrose, and 20% 
sucrose produced the maximum increase in the conformational stability with a change in Tm of 
~4 °C, while Tween-80 had the highest inhibitory effect on aggregation with a change of about 8 
°C. The conformational destabilization caused by Tween-80, however, renders it potentially less 
useful as a stabilizer.  
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 The effects of selected excipients were concentration dependent, except for glycerol and 
Tween-80 (Table 2.2). The use of these excipients at 20% concentration is beyond recommended 
limits due to high osmolarity values. Hence, the use of sorbitol, dextrose and sucrose was limited 
to a concentration of 15%. Tween-80 at concentrations lower than 0.1% was also tested due to its 
inhibitory effect on aggregation despite its conformation-destabilizing effect. 
 The effects of combinations of excipients on thermal transitions (both aggregation and 
conformational stability) are summarized in Table 2.3 (a) and (b). The combinations of selected 
excipients, however, did not yield significant improvements compared to 15% sorbitol alone 
with respect to the stabilization of HAC1. Some combinations of excipients such as 15% sucrose 
and 0.05% Tween-80 showed a stabilizing effect when analyzed by static light scattering. No 
significant effect, however, was observed using intrinsic fluorescence. This is presumably due to 
the non-specific interactions of tween-80 with the protein which inhibits aggregations. In 
contrast, this does not appear to protect a protein against changes in conformation.  
Adjuvant binding studies 
	  
Adsorption and desorption studies of HAC1 with Alhydrogel® 
 The time required for the protein to adsorb onto the surface of an aluminum salt adjuvant 
varies for different proteins. Kinetic studies of HAC1 binding to Alhydrogel® revealed that the 
protein efficiently binds to Alhydrogel® at a protein concentration of 240 µg/ml and an adjuvant 
concentration of 0.5 mg/ml. In 10 mM imidazole buffer (pH 7.0, I=0.15, adjusted with NaCl), all 
of the protein binds to the adjuvant within the first 2 minutes of introducing the adjuvant (data 
not shown). The amount of protein bound to Alhydrogel® does not change significantly during 
the 20-minute period of testing.  
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 The amount of protein that can be adsorbed onto the surface of Alhydrogel®, or the 
“adsorptive capacity” of Alhydrogel®, was determined by constructing adsorption isotherms.  
Adsorptive capacity is defined as the maximum amount of protein that can be adsorbed onto the 
surface of Alhydrogel®. In binding isotherms, 100 µg of Alhydrogel® is able to adsorb up to 160 
µg of protein in 10 mM imidazole buffer (pH 7.0, I=0.15, adjusted with NaCl). In the studies 
conducted, saturation of protein binding was not attained and experiments with higher protein 
concentrations were not conducted.   
 An important study that the FDA requires in the development of a vaccine that involves 
aluminum salts is desorbing the protein from the surface of the adjuvant.  The amount of 
desorbed protein depends on the desorptive media and the level of interaction between the 
protein and the adjuvant. Standard desorptive media such as 1 M NaCl and 1 M urea were not 
able to desorb significant amounts of protein (data not shown). Figure 2.8 shows the effects of 
the combination of urea/citrate and citrate alone on the desorption of three different 
concentrations of the protein adsorbed onto 100 µg of Alhydrogel®. A combination of 1.8 M urea 
and 0.9 M citrate was required to desorb about 80% of the protein from the surface of the 
adjuvant.   
Effect of selected stabilizers on adsorption of HAC1 on Alhydrogel® surface 
 
 The adsorption of HAC1 to the surface of Alhydrogel® may be affected by the presence 
of the excipients that were identified as stabilizers of the protein in solution. The percent protein 
adsorbed to the adjuvant did not change significantly in the presence of the stabilizers (see 
Figure 2.9). Additional excipients including Tween-80 and phosphate were tested as well (data 
not shown), and no significant loss in the adsorption of HAC1 to the adjuvant surface was found.  
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Effect of Alhydrogel adsorption on HAC1 stability  
 
 Intrinsic Trp fluorescence spectroscopy was used to analyze changes in the tertiary 
structure of the protein adsorbed to the surface of Alhydrogel®. At 10 °C, the emission peak 
maximum for HAC1 in solution is at 332 nm, which indicates substantially buried Trp residues 
(Figure 2.10).  The emission peak maximum does not change until about 45 °C, and slowly 
transitions to about 337 nm by 55 oC. This transition at 45 °C represents a surface-induced 
stability perturbation in the tertiary structure of HAC1, since the Tm of HAC1 in solution is about 
54 °C. When the protein is adsorbed to Alhydrogel, the steep transition near 54 °C observed in 
solution is replaced by a very broad and gradual transition that actually initiates as low as 25 °C 
(Figure 2.10). In the presence of sorbitol, dextrose and sucrose, there is no significant 
stabilization of HAC1 on the adjuvant. Tween-80 and phosphate were also tested to see if they 
might help stabilize the adsorbed protein. Figure 2.11 shows the effect of the presence of 5 mM 
phosphate, 15% sorbitol and 0.1% Tween-80 as well as 5 mM phosphate alone on the stability of 
HAC1 adsorbed onto Alhydrogel®. At 10 °C, the position of the emission peak maxima is similar 
to that of HAC1 in solution in both cases. The broad, gradual transitions, however, still exist.  
HAC1 in the presence of 15% sorbitol, 0.1% Tween-80 and 5 mM phosphate showed a thermal 
melting profile closest to that seen in solution. In this case, the transition starts at about 35 °C 
with the Tm for the adsorbed protein found to be about 49 °C. This represents a 5 °C 
destabilization induced by the adsorption of HAC1 onto the surface of Alhydrogel®, compared to 
the 10 °C destabilization described above.  
 Heat treatment, or “annealing”, of the protein was undertaken for 10 minutes at 40, 50 or 
60 °C to see if this could produce a stabilization effect. The position of the emission peak 
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maxima was found to be near 334 nm, which suggests a slight change in structure compared to 
the non-annealed protein (Figure 2.12). When annealed at 40 °C, however, the protein retains 
this conformation until about 40 °C, with the position of the emission peak gradually increasing. 
The Tm for this transition was approximately 54 °C, the same as seen for HAC1 in solution in the 
absence of stabilizers. The extent of this retention of the conformation is not seen when the 
protein was annealed at 50 or 60 °C.  
 Of the formulations tested in this study, five were selected for further evaluation in 
animals based on their ability to best delay the transitions seen by intrinsic fluorescence. These 
formulations included the compounds, sorbitol, sucrose, phosphate and Tween-80. Fifteen 
percent sorbitol with 5mM phosphate and 0.1% tween-80 was used since it showed a profile 
closest to that seen in solution. HAC1 in the presence of 5mM phosphate was also used in the 
animal studies since the phosphate produced slight stabilization of the adsorbed protein. Finally, 
heat-treated HAC1 at 40 °C was also included in animal studies to test if an un-stabilized protein 
might be more immunogenic.  
Immunogenicity of the selected formulations in mice 
	  
 An immunogenicity study in mice was conducted to evaluate effects of formulations on 
HAC1-elicited protective correlates of immunity. In the absence of Alhydrogel®, mice 
immunized with HAC1 formulations with 15% sorbitol or 10% dextrose (groups 1 and 3) 
showed higher serum hemagglutination-inhibition (HAI) antibody titers on study day 35 
compared to the HAC1 formulation with 10% sorbitol and 5% sucrose (group 2, p <0.001). In 
groups 1 and 3, mean HAI titers reached the values of 1:304 (± 138) and 1:154 (± 68), 
respectively, on study day 35, and 100% and 80% of the immunized animals, respectively, 
showed HAI titers of ≥1:40 (Table 2.5). These titers slightly decreased by study day 70 (Figure 
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2.13). In group 3, the mean HAI titer was 1:26 (± 8) on study day 35 and only 40% of animals 
reached HAI titers of ≥1:40 (Table 2.5). In the presence of Alhydrogel® (groups 4–7), mean HAI 
titers were significantly higher than those observed in the groups immunized without 
Alhydrogel®, and were either maintained or slightly increased through study day 35 to 70 with a 
100% seropositive rate (Figure 2.13). No statistically significant difference was observed among 
the groups immunized with Alhydrogel®, except that in group 6 the mean HAI titer was lower 
than in groups 5 and 7 (p <0.05) on study day 35. 
Discussion 
	  
 HAC1 is an H1N1 influenza vaccine candidate containing the recombinant HA protein 
from H1N1 influenza virus A/California/04/09 strain produced in a plant-based system. Only the 
ectodomain of HA is used in HAC1 with the last 77 residues that aid in anchoring the protein to 
the lipid membrane of the virus removed. In this study, we applied a composite biophysical 
approach to characterize HAC1 and identify stabilizers. The signals from various spectroscopic 
and light scattering techniques have been used to monitor changes in the physical structure of 
HAC1 when exposed to stresses such as pH and temperature. The CD spectra of HAC1 show 
predominantly α-helical structure, although there is an indication of the presence of some β-sheet 
character as well. CD secondary structural analysis using K2D2 showed that HAC1 contained 
77% of α-helix and about 1% β-sheet.22 This is consistent with the published crystal structure of 
HA.23 Thermal transitions indicate a gradual loss in the secondary structure with increases in 
temperature at pH 3.0, 4.0, and 5.0. The CD thermal transition at pH 6.0 manifests a sudden 
change in the secondary structure at about 30 °C, which is raised to about 45-50 °C at pH 7.0 and 
8.0. The intrinsic Trp fluorescence melts show emission peak maxima for HAC1 at about 344 
nm at pH 3.0, 4.0, 5.0 and 6.0, and about 340 nm at pH 7.0 and 8.0, when analyzed using the 
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MSM method, which overestimates the peak position by about 8-12 nm. This confirms that 
HAC1 is not completely structurally disrupted at any pH tested, but rather exists in a partially 
perturbed state, with its Trp residues relatively buried under all pH conditions examined. No 
cooperative transitions were detected at pH 3.0, 4.0 and 5.0. At pH 6.0, a thermal transition was 
observed at about ~40 °C and this transition initiates at ~50 °C for pH 7.0 and 8.0. Static light 
scattering and extrinsic ANS fluorescence also revealed similar trends in the protein’s thermal 
transitions. ANS was found to bind to HAC1 at low temperature at pH 3.0, 4.0, and 5.0 
presumably due to the partially altered structure.  
 All the data collected for HAC1 was combined in the form of an EPD to better represent 
the effect of temperature and pH on the protein. The three distinct regions in the EPD 
presumably reflect the conformational changes that HA undergoes when influenza virus infects a 
cell 24-26. At physiological pH, the protein is in its native form. HA binds to sialic acid residues 
on the cell surface, which causes the host cell to internalize the virus into an endosomal 
compartment. When the pH of the endosome drops below 6.0, the conformation of HA alters, 
resulting in the exposure of apolar regions. This new form attaches itself to the endosomal 
membrane. As the pH further drops to about 5.0, HA again changes its structure causing the 
membrane of the virus to fuse with that of the endosome, propelling viral RNA into the 
cytoplasm. Thus, the conformational changes that occur at different pH values during natural 
virus infection appear to be reflected in the EPD.  
Since HAC1 was found to be most stable at pH 7.0 and 8.0, pH 7.0 was chosen to screen 
for stabilizers and further formulation studies. Imidazole buffer was selected for the screening 
studies. Since phosphate can convert aluminum hydroxide into aluminum phosphate and citrate 
is known to dissolve the aluminum salt adjuvants, both of which can affect antigen binding 
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properties, citrate phosphate buffer was not used for further studies. Surfactants such as Tween-
80, sugars and sugar alcohols such as dextrose and sorbitol showed the highest degree of 
stabilization with respect to aggregation with an increase in Tm of ~7 oC. Although Tween-80 
stabilized the protein against aggregation, it did not significantly protect it against thermally 
induced conformational changes at concentrations of 0.05 - 0.1%. It has been suggested that 
polyalcohol and sugars delay or inhibit aggregation by enhancing the stability of native-like 
protein structures. Extensive studies have been reported on this kind of stabilization through 
nonspecific processes such as preferential hydration.27-29 The potential for stabilization via 
specific interactions, however, cannot be eliminated due to similarities in the chemical structure 
between some stabilizers and sialic acid which is a natural ligand for the HA protein. 
Destabilization and enhanced aggregation of HAC1 in the presence of a polyanion (dextran 
sulfate) is presumably due to the formation of HA-polyanion complexes. Tween-80 is known to 
often exert protective effects on protein aggregation through direct interaction with the protein or 
via its effect on air and water interfaces. In this case, however, the conformational destabilization 
caused by Tween-80 renders it potentially less useful in formulation development. Sorbitol, 
dextrose, and sucrose produced the highest increases in Tm values. Concentrations of 15% or 
below were selected for combination studies to minimize high osmolarity values.  
When using aluminum salt adjuvants, the antigen is typically adsorbed onto the surface of 
the adjuvant. A high level of unbound protein adjuvanted with Alhydrogel® has been associated 
with hypersensitivity reactions as shown for some malaria antigens in clinical trials.30-32 Several 
ideas have been proposed over that last 80 years to explain the mechanism of 
immunopotentiation by aluminum salt adjuvants. The depot theory postulates that the aluminum 
adjuvant and the adsorbed antigen remain at the site of injection.33 The slow release of antigen 
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from the adjuvant stimulates antibody production. Another theory suggests that the adjuvant 
causes inflammation at the site of injection, attracting antigen presenting cells (APCs).34 A third 
idea postulates that particulation of an antigen may occur on the surface of the adjuvant, which 
results in antigen internalization by macrophages via phagocytosis leading to an enhanced 
immune response. Recently, it was proposed that upon interaction of dendritic cells (DCs), the 
key APCs, with an adjuvant, DCs’ lipid membrane undergoes re-assortment which leads to the 
antigen being delivered in its soluble form into DC followed by processing in the MHC class II 
compartment, which ultimately shows a high preference for activation of CD4+ T-cells that in 
turn activate B-cells and increase an antibody response.35 It is possible that some these 
mechanisms contribute to immunopotentiation by aluminum salt adjuvants. Recent studies have 
also suggested that in some cases retention of an antigen on an adjuvant is not essential for 
immunopotentiation.36 Nevertheless, adsorbing the antigen onto the surface of the aluminum salt 
adjuvant is a common approach to produce an optimal immunogenic effect. 
 The PI of HAC1 is around 6.5. This gives the protein a negative charge at pH 7.0. Due to 
simple electrostatic interactions, HAC1 should adsorb onto positively charged Alhydrogel®. This 
is in a good agreement with the experimental data. Other interactions such as van der Waals 
forces may play an important role in the adsorption process as well. Here, almost all of the 
protein is found to be bound to Alhydrogel® within the first 2 minutes of introduction. The 
adsorption isotherm demonstrates a very high adsorption capacity for HAC1 with 100 µg of 
Alhydrogel® able to adsorb 160 µg of HAC1. The inability of NaCl to desorb the protein from 
the surface of Alhydrogel® suggests that the binding is not purely electrostatic in nature. The 
presence of strong desorptive agents such as a combination of urea and citrate resulted in 
desorption of about 80% of the protein from the surface of Alhydrogel®. The stability of the 
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protein, however, was found to be decreased when adsorbed onto the surface of Alhydrogel®. 
Several studies have demonstrated that adsorption of a protein onto the surface of aluminum salts 
generally has a negative effect on the thermal stability of the protein.20,37 When the protein is 
heated, there is a gradual change in the position of the emission peak maximum, replacing the 
cooperative unfolding transition that occurs at about 45 °C in solution with one 10 °C less. This 
may be due to a time-dependent optimization of interactions between the protein and the surface 
of the adjuvant. In a few cases, it was possible to partially overcome this effect. This decreased 
stability may also lead to enhanced chemical degradation. Deamidation is especially a concern. 
This is due to the high pH in the microenvironment of the protein on the surface of Alhydrogel®. 
The positively charged surface of the adjuvant repels protons and attracts OH- ions, thereby 
increasing pH and making deamidation more likely to occur. The high surface pH can be 
countered by using sodium phosphate. Sodium phosphate can partially convert the positively 
charged surface of Alhydrogel® to aluminum phosphate lowering the surface pH. As seen is this 
study, sodium phosphate at a concentration of 5 mM was, in fact, able to stabilize the adsorbed 
protein to some extent. Actual studies of the chemical stability of HAC1 have not yet been 
conducted.   
 The effects of adding excipients and/or stabilizers on the immunogenicity of the HAC1 
vaccine were also evaluated. The addition of 15% sorbitol or 10% dextrose resulted in the 
induction of higher serum HAI antibody titers in mice compared to the addition of 10% sorbitol 
and 5% sucrose. This suggests that sorbitol or dextrose may have a stabilizing effect, as 
described in the Results section, and improve the immunogenicity of the HAC1 vaccine. Serum 
HAI titers, however, gradually decreased from study day 35 through study day 70, while the HAI 
titers in mice immunized with HAC1 plus Alhydrogel® were maintained at same levels up to 
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study day 70, perhaps due to a depot effect of the aluminum adjuvant. In previous studies, we 
reported the ability of the plant-produced HAC1, at doses of 15 or 5 µg in saline plus 
Alhydrogel® (1:10 [w:w] of aluminum), to elicit HAI antibody titers ≥1:40 in 100% of 
immunized mice. In addition, immunization with 15 or 5 µg of HAC1 in the absence of 
Alhydrogel® elicited HAI antibody titers ≥1:40 in 83 or 50% of mice, respectively. According to 
the FDA’s recommendation38, however, the amount of aluminum in a dose of a biological 
product should not exceed 1.14 mg, if determined by calculation on the basis of the amount of 
aluminum compound added. Therefore, in the current study, we investigated whether vaccine 
formulations containing a lower, more acceptable amount of aluminum or no aluminum adjuvant 
at all could still elicit significant antibody responses. The results obtained indicate that 
immunization with HAC1 plus a lower amount (0.5 mg/ml) of aluminum can still elicit 
significant HAI antibody responses with 100% of animals generating HAI antibody titers ≥1:40. 
Interestingly, in the absence of Alhydrogel, the addition of 15% sorbitol resulted in the 
generation of equal or greater HAI responses compared to those induced by HAC1 in saline 
without Alhydrogel® as reported on previously. These results need to be further investigated in a 
dose-reduction study to determine how the buffer and excipients tested in the current study 
affected the robustness of the HAI antibody responses, particularly with regard to the lower 
amount of Alhydrogel® tested. In addition, no statistically significant differences in HAI titers 
were observed between the group of mice immunized with heat-treated HAC1 plus Alhydrogel® 
and the other HAC1/Alhydrogel® groups. Similar results were observed when total IgG titers 
elicited by the different immunizations were analyzed (data not shown). Although our results 
demonstrate that heat-induced structural changes did not affect the immunogenicity of HAC1 in 
terms of the magnitude of total IgG and HAI responses induced, comparison of virus-
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neutralization antibody titers between animals immunized with structurally altered HAC1 versus 
non-denatured HAC1 would provide important additional information about the high 
temperatures have on the immunogenicity of HAC1. In summary, the results of this study 
demonstrate that the amount of Alhydrogel® in the HAC1 vaccine could be spared down to 0.5 
mg/ml, the same amount of aluminum used in GARDASIL, the FDA-approved human 
papillomavirus vaccine (Merck & Co., Inc., Whitehouse Station, NJ).  
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Introduction 
	  
 Streptococcus pneumoniae is the leading cause of pneumonia, bacteremia, and meningitis in the 
United States and worldwide. Systemic infections and invasive pneumococcal disease (IPD) are caused by 
the spread of the bacteria in the blood stream. It is estimated in the US alone, that over 40,000 lives are lost 
to S. pneumoniae-related diseases with pneumococci being responsible for over 500,000 cases of 
pneumonia each year.1 Furthermore, pneumonia is the leading cause of childhood death and claims the lives 
of about 1.4 million children under the age of five every year, which is more than HIV, tuberculosis and 
malaria combined. S. pneumoniae is estimated to be the cause of over a third of those cases of pneumonia.2,3 
Current vaccines against the pathogen include a polysaccharide vaccine, and a carbohydrate conjugate 
vaccine.4,5 The polysaccharide vaccine is approved for use in adults (65 years or older) and protects against 
up to 23 different serotypes of the bacteria. Unfortunately, this vaccine is poorly immunogenic in children 
below the age of 2 years, and in the elderly, especially those with compromised immune systems.5,6 The 
conjugate vaccine is more immunogenic and approved for use in children7,8 , and was recently approved by 
FDA for use in adults 50 years of age and older.  This vaccine, however, does not protect against all 
serotypes of the pathogen.4,5 The geographical distribution of the pathogen also makes it hard to identify a 
single efficacious vaccine for the entire world. There is a high level of complexity involved with the 
manufacturing of the conjugate vaccines, making them expensive and less-accessible to the majority of the 
world population who are most in need.  
These limitations have spurred research into the development of a cost effective vaccine that is 
targeted against the majority of pneumococcal serotypes. Protein-based vaccines are among one of the 
approaches currently being taken towards producing a cheaper and more cross protective vaccine. Several 
surface proteins from Streptococcus pneumoniae are being evaluated for use as antigens in such vaccines. 
The pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC), pneumococcal 
surface adhesion A (PsaA), and serine-threonine protein kinase (StkP), as well as other essential proteins 
such as protein required for cell wall separation of group B streptococcus (PcsB) and pneumolysin (Ply) are 
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attractive candidates for use as vaccine antigens4. StkP and PcsB have previously been identified as antigens 
by the ANTIGENome technology.9 Vaccines consisting of protein antigens are expected to be more 
immunogenic than their conjugate counterparts, especially in children and the elderly. They are also 
expected to address the coverage problem since 98-100% of the serotypes contain one or more of these 
surface proteins. In addition, a vaccine based on a few protein antigens is likely easier and cheaper to 
manufacture than multivalent carbohydrate-conjugate vaccines. There may also be the added advantages of 
using protein antigens from a stability point of view because they may be more easily characterized. Highly 
purified, recombinant protein antigens are usually not highly immunogenic by themselves and therefore 
usually require an adjuvant to boost their immunogenicity. The most common adjuvants used in the world 
today are aluminum hydroxide (Alhydrogel®) and aluminum phosphate (Adjuphos®). Protein antigens are 
typically adsorbed to the surface of these aluminum salt adjuvants for maximum effectiveness.  
In this paper, we describe the biophysical characterization, stabilization and initial formulation 
development evaluations of a trivalent recombinant protein based vaccine against Streptococcus 
pneumoniae consisting of PsaA , StkP  and PcsB fragments (furthermore mentioned as SP1650, SP1732 and 
SP2216 respectively) in the presence of aluminum salt adjuvants (Alhydrogel®, Adjuphos®).  
Materials and Methods 
	  
The three purified antigens SP1650 (PsaA), SP1732 (StkP), and SP2216 (PcsB) were supplied by 
Intercell AG (Vienna, Austria) as frozen solutions in a 10 mM Tris buffer containing 70 mM sodium 
chloride, at pH 7.5. The SP1732 solution also contained 0.2% (w/v) polysorbate-20. For the initial 
biophysical characterization, all three of the proteins were dialyzed into 20 mM citrate phosphate (CP) 
buffers (pH 5.5, 6.0, 6.5, 7.0, 7.5 and 8.0) with a total ionic strength of 0.15 (adjusted with NaCl).  All 
excipients were purchased from Sigma-Aldrich (St. Louis, MO). For excipient screening and adjuvant 
studies, 10 mM sodium acetate buffer (containing 0.067% w/v polysorbate-20) was used for all three 
proteins. All other reagents were of analytical grade. Protein concentration was determined by UV 
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absorbance at 280 nm using an extinction coefficient of 1.1 ml/mg-cm for SP1650, 0.468 ml/mg-cm for 
SP1732 and 0.1 ml/mg-cm for SP2216. 
Characterization of Physical Stability:  
Sample preparation:  
For each of the spectroscopic techniques, duplicate samples were prepared at different pH values 
(pH 3 to 8, at one unit intervals) by dilution of the stock material with 20 mM CP buffer of the 
appropriate pH. The ionic strength of samples was kept constant at 0.15 using appropriate amounts of 
NaCl. Protein solutions were studied at a concentration of 0.2 mg/ml for the CD studies, 0.1 mg/ml for 
the fluorescence studies and 0.3 mg/ml for second derivative UV absorbance studies.  
Far-UV Circular Dichroism (CD) Spectroscopy:  
CD spectra were acquired using a Jasco J-810 spectropolarimeter equipped with a 6-position 
peltier temperature controlled sample cell holder. CD spectra were obtained from 260-190 nm. Melting 
curves of the proteins were constructed by plotting the CD signal at 222 nm at a 2.5oC interval between 
10 and 87.5oC. Secondary structure analysis was done using CDNN software v2.1 after baseline 
correction of the obtained spectra (200-260nm).   
Intrinsic Tryptophan (Trp) Fluorescence Spectroscopy:  
Intrinsic fluorescence spectra were acquired using a Photon Technology International (PTI) 
spectrofluorometer (Lawrenceville, NJ) equipped with a turreted 4-position peltier-controlled cell holder. 
The Trp residues in the protein were excited at 295 nm, and the emission spectra were collected from 310 
to 400 nm. Light scattering data were also collected at 295 nm using a second detector located at 180O 
angle to the emission detector. Fluorescence spectra were collected every 2.5oC over a ranger of 10oC and 
87.5oC. Peak positions and intensities of the emission spectra were obtained using a mean spectral center 
of mass method (msm) which overestimates the actual peak positions by about 10 nm.  
ANS Fluorescence Spectroscopy:  
Unfolding of the protein with increasing temperature was also monitored by fluorescence 
emission of the extrinsic probe 8-Anilino-1-naphthalene sulfonate (ANS). An optimized 15 molar excess 
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of ANS was added to the protein solution. The ANS was excited at 375 nm and the emission spectrum 
was collected from 400-600 nm every 2.5oC over the temperature range of 10 – 87.5oC. Peak intensity of 
the emission spectra was monitored at 475 nm.   
Second Derivation UV Absorbance Spectroscopy:  
Changes in the tertiary structure of SP2216 were monitored by second derivation UV absorbance 
spectroscopy. High resolution absorbance spectra were obtained using an Agilent 8453 UV-Visible 
absorbance spectrophotometer. Absorbance spectra were recorded from 10 to 90oC at increments of 2.5oC 
over the wavelength range of 200-400 nm. The second derivative was calculated using a nine-point data 
filter and third order Savitzky-Golay polynomial with the Chemstation software provided by Agilent. The 
second derivative data was then imported into origin to calculate peak shifts.  
Empirical Phase Diagrams (EPDs):  
CD molar ellipticity at 222 nm, intrinsic Trp fluorescence peak intensities and peak shifts, static 
light scattering and ANS fluorescence peak intensity data sets were used for the construction of the 
empirical phase diagrams. For SP2216, intrinsic fluorescence spectroscopy could not be used due to the 
absence of Trp in the protein. Therefore, second derivative UV absorption spectroscopy was used instead 
for the construction of the phase diagram. A more detailed description of the construction of the phase 
diagrams can be found in previously published papers. 10-12 
Excipient Screening:  
A common buffer consisting of 10 mM sodium acetate, pH 5.5 and 0.067% polysorbate-20 was employed 
for the excipient screening work. The ionic strength was kept constant at 0.15 with NaCl. In experiments 
with no NaCl, however, sodium acetate was the sole contributor to the ionic strength lowering the ionic 
strength significantly.  
Intrinsic tryptophan (Trp) fluorescence spectroscopy was used to screen for stabilizers for SP1650 
and SP1732 antigens. Circular dichroism spectroscopy was used to screen for stabilizers of SP2216. 
Fluorescence and CD spectra of each protein in the presence of various GRAS (Generally Regarded as 
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Safe) excipients were obtained as previously described and thermal melting curves were constructed to 
determine the melting point (Tm) of each protein in the presence of different excipients. The extent of 
stabilization by the excipients was measured by their ability to shift the Tm of each protein to higher 
temperatures compared to protein in the absence of excipient. After stabilizers for all three proteins were 
identified, studies were performed to optimize their concentrations. Different stabilizers were evaluated in 
various combinations to determine if any additive or synergistic effects could be obtained for stabilization 
of the proteins.  
Adjuvant Studies: 
Experiments in the presence of the adjuvants were conducted by adding Alhydrogel® or 
Adjuphos® to the protein. The buffer used for the adjuvant studies was 10 mM sodium acetate at pH 5.5, 
containing 0.067% Tween-20. No sodium chloride was added to decrease the osmolarity of the 
formulations.  Manganese chloride (50 µM) was added to all the formulations due to its impact on the 
stability of SP1650.  
The three protein antigens were first tested separately to determine whether they adsorb 
preferentially to aluminum hydroxide (Alhydrogel®) or aluminum phosphate (Adjuphos®). This was 
done by adding 70 µg of protein to 50 µg of adjuvant. The amount of unadsorbed protein was determined 
by measuring the amount of protein in the supernatant using UV absorbance spectroscopy after 
centrifugation. An adsorption isotherm was constructed for each of the protein in the presence of 0.25 
mg/ml Alhydrogel® at various protein concentrations (0.1 – 0.7 mg/ml at 0.1 unit intervals).  Desorption 
of the proteins from the adjuvants was evaluated in the presence of various concentrations of several 
desorption agents including sodium chloride, urea, sodium citrate, and guanidine hydrochloride. After 
suspending the protein-adsorbed adjuvant in the desorption media, the amount of the protein desorbed 
was measured by UV absorbance spectroscopy after centrifugation.  
 The thermal stability of the aluminum adjuvant adsorbed protein was assessed by intrinsic 
fluorescence in the case of SP1650 and SP1732 proteins. The protein (SP1650 or SP1732) was adsorbed 
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onto Alhydrogel® in a 1 mm cuvette using the procedure described above. The suspension was then 
allowed to settle for 4 hours. The pellet was then analyzed by intrinsic fluorescence spectroscopy between 
10 and 87.5oC at 2.5o intervals. The stability of SP2216 was assessed by FTIR spectroscopy.  
FTIR Spectroscopy:  FTIR spectra of SP2216 were obtained using a Bruker Tensor-27 FTIR spectrometer 
(Bruker Optik GmbH, Germany) equipped with a BioATR II cell containing a Zinc Selenide (ZnSe) 
crystal. The spectra were collected from 4000 to 900 cm-1 at temperatures ranging from 10 to 90oC every 
2.5oC. Second derivative spectra were calculated using the Savitzky-Golay algorithm. Intensity changes 
were monitored at 1620 cm-1. Changes at 1620 cm-1 are generally associated with vibrations in inter-
molecular beta sheet structure that is often prevalent in protein aggregates. 13 
Results 
Biophysical Characterization and excipient screening of the three antigens 
	  
The biophysical characterization of SP1650 was accomplished using circular dichroism, intrinsic 
fluorescence, ANS fluorescence spectroscopy, and static light scattering. The data obtained from these 
methods as a function of pH and temperature are shown in Figure 3.1. Figure 3.1A shows the circular 
dichroism spectra at various pH values at 10oC. The spectra at pH 4 to 8 display a broad peak with double 
minima at 208 nm and 222 nm. At pH 3, a significant loss of ellipticity was observed along with the 
disappearance of the double minima seen at other pH values. CD secondary structure analysis indicated 
that SP1650 contained approximately 46% α-helices, 26% β sheets and 25% random coil. Figure 3.1B 
shows the change in circular dichroism signal at 222 nm as a function of temperature for SP1650. Small 
transitions were seen at about 30oC for SP1650 at pH 3 and 4. At pH 3, another slight transition was 
observed at about 60oC. At pH 5-8, a sharp decrease in the CD signal was seen at about 50oC. Figure 3.1C 
shows changes in the tryptophan fluorescence peak position maximum as a function of temperature. At 
pH 3, a slight transition was again observed at 30oC, with a second transition at about 60oC. SP1650 
showed a single transition at about 30oC at pH 4. At pH 5-8, SP1650 displayed a two transition melting 
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curve, the first of which occurred at about 50oC, followed by a second transition at about 65oC. Figure 
3.1D shows the changes in the tryptophan fluorescence peak intensity as a function of temperature. 
Except for pH 3, which showed no transitions, SP1650 displayed transitions similar to those seen using 
CD and intrinsic fluorescence spectroscopy. Figure 3.1E shows the changes in ANS intensity as a 
function of temperature. The ANS intensity at pH 3 is very high even at low temperature, when compared 
to the other pH values. An increase in intensity was observed at 30oC at pH 4. At the pH values of 5-8, 
increases in ANS intensity were noticed as early at 45oC. The increase in ANS intensity is thought to 
correspond to the dye binding to apolar regions of the protein, which are exposed as the protein starts to 
unfold. Figure 3.1F shows the changes in light scattering intensity. Light scattering was monitored using a 
second detector 180O to the intrinsic fluorescence detector, and was monitored at 295 nm, which was the 
incident wavelength used to excite tryptophan residues. No significant increase in light scattering was 
seen at pH 3. In fact, a slight decrease in scatter intensity was seen for SP1650 at pH 3 at higher 
temperatures. At pH 4, 5 and 6, an increase in light scattering was observed at 30oC at pH 4, and about 
57.5oC at pH 5 and 6. No significant transitions were observed at pH 7 and 8.  
An empirical phase diagram (EPD) was constructed using the data shown above (Figure 3.1G). 
The EPD displays three distinct regions. Region I was identified as the native state of the protein at pH 
values between 4 and 8 at low temperatures. Based on these data, it appears that SP1650 exists in a 
conformationally altered state at pH 3 (Region III). Region II was identified as another region at pH 
values from 4-8 at higher temperatures where the protein was also structurally altered. There appears to 
be no notable aggregation of the protein at higher temperatures at pH 7-8 (light green), but extensive 
aggregation at pH 4-6 (darker green).  
The EPD suggests that SP1650 is only moderately stable as a function of pH and temperature. In 
an effort to stabilize the protein further, a library of GRAS excipients were screened to identify potential 
stabilizers. Figure 3.1H shows the effect of selected compounds on intrinsic fluorescence melts of 
SP1650. This includes destabilizers such as arginine and histidine, stabilizers such as sorbitol and 
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dextrose, and excipients that do not affect the stability of the protein such as calcium chloride and 
dextran-70.  The ability of a compound to stabilize SP1650 was measured by its ability to delay the 
transition seen at about 50oC. The melting temperature (Tm) or the mid-point of the transition was 
determined by identifying the peak maximum of the first derivative of the melting curve. Table 1 lists the 
change in Tm of SP1650 for the excipients tested. The concentrations of the most promising stabilizers 
were then optimized. Stabilizers were also tested in combinations to check for additive or synergistic 
effects. Table 2 summarizes the changes in Tm of SP1650 at various concentrations of selected 
excipients, and the Tm of SP1650 for selected excipients tested in combinations are shown in 
Supplementary Table S1. Manganese chloride and sugars such as sorbitol were shown to best stabilize 
SP1650. To use the maximum amount of stabilizer, but keep the total solution osmolarity as low as 
possible, sodium chloride was removed from the formulation buffer.  
 The biophysical characterization of SP1732 was performed using intrinsic fluorescence, circular 
dichroism spectroscopy and static light scattering experiments. These data are shown in Figure 3.2A-2E. 
Extrinsic fluorescence experiments with ANS were not conducted due to the presence of polysorbate-20. 
Figure 3.2A shows the CD spectra at 10oC for SP1732 at pH values from 3 to 8. No significant 
differences were seen in the CD spectra for SP1732. Secondary structure analysis of SP1732 CD spectra 
suggested approximately 82% α-helices, 13% β sheets and 8% random coil. A double minimum was 
noted at 208 and 222 nm indicative of the presence of alpha helices. Changes in the molar ellipticity at 
222 nm as a function of pH and temperature are shown in Figure 3.2B. An increase in CD signal was seen 
at about 45oC at pH 3, followed by a drastic decrease at about 50oC. The same effect was seen at pH 4 and 
5 at about 55oC and 65oC, respectively. The transition in CD signal was seen for pH 6, 7 and 8 only at 
about 75oC. Figure 3.2C shows the changes in intrinsic fluorescence peak position as a function of pH and 
temperature. As observed above, the transition at pH 3 starts at lower temperature, near 45oC. This 
transition was delayed to about 55oC at pH 4, and 65oC at pH 5. At pH 6, 7 and 8 the transition was 
observed at about 75oC. Very similar trends were noted when analyzing the changes in peak intensity as 
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well, as shown in Figure 3.2D.  Static light scattering data are shown in Figure 3.2E. Similar trends were 
seen to those described earlier. The formation of protein aggregates was observed at 45oC at pH 3, and at 
55oC and 65oC at pH 4 and 5, respectively.  
An EPD for SP1732 was constructed using these data (Figure 3.2F). Region I was assigned to the state in 
which the protein exists in its native form and is most stable. Region III was identified as a region in 
which large changes in structure occur and aggregation is displayed. In region II, the protein exists in a 
molten globule-like state, characterized by a loss in the tertiary structure, but maintains the protein’s 
secondary structure. Overall, SP1732 was found to be relatively resistant to changes in pH and 
temperature. A library of GRAS excipients was screened to determine if any of the compounds were able 
to further stabilize SP1732. Intrinsic tryptophan fluorescence spectroscopy was again used to screen for 
potential stabilizers. Candidate stabilizers were selected based on their ability to delay the transition seen 
at about 72.5oC at pH 6. Due to the incomplete nature of this transition, the onset temperatures of the 
thermal transitions of SP1732 were used. Supplementary Table S2A lists the transition onset temperatures 
of SP1732 for all the compounds tested as analyzed by changes in the fluorescence emission peak 
position and intensity. Sugars such as sucrose, dextrose, and lactose showed a stabilizing effect, whereas, 
compounds such as cyclodextrins and malic acid produced a destabilizing effect. Selected stabilizers were 
tested in different concentrations to see if lower amounts of stabilizer were sufficient to stabilize the 
protein while lowering the osmolarity of the formulations. The effect of excipient concentration on the 
transition onset temperature of SP1732 is shown in Supplementary Table S2B. The most promising 
stabilizers were also tested in combinations to check for additive/synergistic effects and these results are 
shown in Supplementary Table S2C.  
The protein SP2216 was characterized in a similar manner using multiple biophysical techniques. 
Due to the absence of tryptophan residues in the protein, intrinsic fluorescence spectroscopy could not be 
used. Instead, second derivative UV absorbance spectroscopy was employed, in addition to circular 
dichroism, extrinsic fluorescence spectroscopy and light scattering methods. Figure 3.3A shows the CD 
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spectra of SP2216 at different pH values at 10oC. Again, a double minimum was seen at about 208 nm 
and 222 nm, characteristic of alpha helices. The signal did not vary significantly with changes in pH. CD 
secondary structure analysis of SP2216 implied that the protein contained roughly 28% α-helices, 38% β 
sheet, and 38% random coil. Figure 3.3B shows the changes in CD signal at 222 nm as a function of 
increasing temperature. At all pH values, significant loss in negative ellipticity was evident with 
transitions initiating at about 15-20oC indicating that SP2216 is an extremely thermolabile protein. The 
CD melt results suggest that the protein is slightly more thermally stable at about pH 5 and 6 compared to 
other pH values, based on onset temperatures. Figure 3.3C shows data from static light scattering studies. 
No significant increase in light scattering intensity was observed at pH values of 6, 7 and 8. At lower pH 
values, however, significant increase in scattering was observed at about 45oC, indicating aggregation of 
the protein. At pH 3, the protein displayed the maximum increase in scattering. Figure 3.3D shows the 
changes in ANS intensity as a function of temperature for SP2216 at the various pH values. It should be 
noted that the ANS intensity was found to be elevated at 10oC at all pH values examined indicating some 
level of binding of the dye even at low temperature. Based on the ANS studies, the SP2216 protein was 
found to be relatively more stable at pH 5 than other pH values with its transition starting at about 35oC. 
Data obtained from 2nd derivative UV absorbance spectroscopy is shown in Figure 3.3E. The thermal 
melts show the second derivative peak shifts at 284 nm as a function of pH and temperature. These shifts 
arise from changes in the environment around the tyrosine residues as the protein unfolds with increasing 
temperature. The 2nd derivative peak shifts again confirmed that SP2216 displayed changes in its tertiary 
structure at the relatively low temperatures of about 20-30oC. SP2216 was again found to be relatively 
more stable at pH 5 by 2nd derivative UV absorbance spectroscopy with the transition starting at about 
30oC. At pH 3, SP2216 did not display any detectable transitions. At all other pH values, SP2216 
displayed transitions at temperatures ranging from 20-30oC.  
The EPD for SP2216 was then constructed using the biophysical data discussed above as shown 
in Figure 3.3F. The EPD can be divided into three unique structural regions. Region I from pH 5 to 8 at 
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low temperatures is the region where the protein presumably exists in its native conformation. Increases 
in temperature at these pH values (region II in the phase diagram) lead to conformational changes in the 
protein as evidenced by changes in circular dichroism and fluorescence spectra. Region III comprises the 
pH 3 and 4 states at all temperatures where protein is thermally very labile and is in a variety of non-
native aggregation-prone states. Overall, SP2216 was found to be very sensitive to temperature, with 
changes in structure occurring at room temperature. A library of GRAS excipients was screened using 
circular dichroism spectroscopy to identify stabilizers. Supplementary Table S3A lists the excipients that 
were tested along with the Tm and change in Tm for the protein. Sugars and sugar alcohols such as 
sucrose and sorbitol stabilized SP2216 with an increase in Tm of about 10oC at concentrations of 20% 
(w/v).  Arginine and guanidine were both found to destabilize the protein. Concentration studies revealed 
a progressive increase in Tm values of SP2216 with increasing concentrations, as shown in 
Supplementary Table S3B. The effect of using combinations of selected excipients on the Tm of SP2216 
is shown in Supplementary Table S3C. 
For ease of comparison, Table 3 lists the effect of selected stabilizers and destabilizers on the 
thermal unfolding temperature (Tm) of each of the three protein antigens. Sugars and sugar alcohols, for 
example such as sucrose and sorbitol, showed stabilizing effects on the conformational stability of all 
three proteins. In contrast, additives such as arginine, dextran sulfate, diethanolamine and guanidine 
destabilized one or more of the three proteins. Interestingly, sodium citrate was able to stabilize SP1650, 
but not SP1732 and SP2216.  
Adjuvant Studies 
	  
The binding of all three antigens, SP1650, SP1732 and SP2216 to two different aluminum salt 
adjuvants, Alhydrogel and Adjuphos, was studied individually. 10 mM sodium acetate buffer at pH 5.5 
was used for all the adjuvant studies. Each of the proteins was found to bind preferably to Alhydrogel, 
with nearly complete binding. Figure 3.4 shows the percent protein bound in the presence of Alhydrogel 
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and Adjuphos. When 70 µg of each antigen was added to 50 µg of Alhydrogel, over 90% of each antigen 
was found to rapidly bind (in less than a minute). When added to Adjuphos, however, only 50-60% of the 
protein was found to be bound. With an isoelectric point (pI) of ~5.1, SP1650 has a slight negative charge 
at pH 5.5, and hence binds to the positively charged Alhydrogel. SP2216 has a pI of ~5.3, and SP1732 has 
a pI of ~6.0. Both of these latter proteins thus have low or minimal total negative charge at pH 5.5. Their 
binding to Alhydrogel may be at least partially due to interactions other than simple electrostatic contacts. 
Figure 3.5 shows that Alhydrogel demonstrated a high adsorption capacity for all three proteins. 50 µg of 
Alhydrogel was able to adsorb up to 90 µg of SP1650, SP1732 and SP2216. The anticipated dose in the 
final vaccine formulation is 600 µg of Alhydrogel with 50 µg of each antigen.  
Desorption of each of the absorbed proteins from the surface of the aluminum salt adjuvant was 
studied in the presence of various agents such as urea, citrate, guanidine hydrochloride, and NaCl. 
Solutions containing 2M NaCl or 2M urea were not able to desorb significant amounts of protein from the 
adjuvant. The combination of 2M urea and 1M sodium citrate, however, was able to desorb about 80% of 
SP1650 from Alhydrogel. This solution, however, was able to desorb only 10-15% of protein in the case 
of SP1732 and SP2216. A solution containing 2M Guanidine was able to desorb over 80% of SP1732 and 
SP2216 from Alhydrogel, however, it was unable to desorb significant amounts of SP1650 from the 
adjuvant. Figure 3.10 shows the amount of protein desorbed. In summary, the protein antigens SP1732 
and SP2216 were best desorbed from Alhydrogel using 2M Guanidine, and SP1650 was desorbed using a 
solution containing 1M sodium citrate and 2M urea.  
The conformational stability of SP1650 and SP1732 on the surface of the aluminum salt adjuvant 
was assessed by intrinsic fluorescence spectroscopy. The position of the emission peak maxima was 
monitored as a function of temperature. Protein (200 µg/ml) was added to Alhydrogel® (0.5 mg/ml) by 
the procedure described above, which ensures >90% bound protein. Figure 3.6 shows the melting curve 
for SP1650 in solution and while adsorbed to the adjuvant surface. In solution, SP1650 shows a transition 
at about 70oC in the presence of 5% sorbitol and 50 µM MnCl2.  When adsorbed onto the adjuvant, the 
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SP1650 thermal transition initiates much earlier, showing some peak shifts above 30oC. The decrease in 
stability of the protein on the adjuvant surface was not modified by the addition of previously identified 
stabilizers. The effect of the addition of sodium phosphate on the stability of the adsorbed SP1650 protein 
is also shown in Figure 3.6. The addition of as little as 5 mM sodium phosphate was able to delay the 
transition to about 55oC. When proteins are adsorbed on to Alhydrogel, they are frequently, although not 
always, destabilized. In contrast, the SP1732 protein was found to be more stable on the surface of the 
adjuvant. Figure 3.7 shows the intrinsic fluorescence melting curves for SP1732 in solution, and while 
adsorbed onto the adjuvant. The differences seen in the peak positions probably arise from the nature of 
the data analysis. The msm method, used to calculate the position of the emission peak maxima, 
overestimates the peak position by about 8-12 nm. The true emission peak maxima for SP1732 is the 
same in solution and while adsorbed on the adjuvant, as shown in the representative intrinsic fluorescence 
spectra of SP1732 at 10oC in solution and bound to the adjuvant in Figure 3.8. No significant differences 
were seen in the stability of SP1732 upon addition of stabilizers or sodium phosphate.  
The stability of SP2216 while adsorbed to Alhydrogel was analyzed by alternative methods other 
than fluorescence spectroscopy due to the absence of an intrinsic fluorophore.  FTIR was employed to 
access the stability of SP2216 on the surface of the adjuvant. Figure 3.9 shows the second derivative 
FTIR peak intensity changes at 1620 cm-1 as function of temperature.  In solution, a small transition is 
seen at about 40oC. The increase in intensity at 1620 cm-1 at 40oC may hint at the formation of 
intermolecular beta sheets (i.e., protein aggregation). Representative second derivative FTIR spectra of 
SP2216 at different temperatures are shown in Figure 3.11. In addition to the increasing intensity of the 
negative peak at 1620cm-1, a decrease in intensity of the peak at 1650cm-1was also observed. Analyses at 
these wavelengths which reflect α-helical and β-sheet content revealed transitions initiating at similar 
temperatures as shown in Figure 3.9 (data not shown). When SP2216 is adsorbed to Alhydrogel, the 
intensity of the thermal transition is lowered, but the structural transition initiates at about the same 
temperature. The increase in intensity seen may be explained by slight concentration differences or better 
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packing of the adjuvant on the bioATR II crystal.  This result suggests that the adsorption of the SP2216 
protein on Alhydrogel does not have a major effect on its stability. The thermal transition of SP2216 
adsorbed on the Alhydrogel surface does not seem to be affected by previously identified excipients that 
stabilized the protein in solution.  
Discussion 
	  
The structural integrity and conformational stability of three candidate vaccine protein antigens, SP1650, 
SP2216 and SP1732, were separately characterized in solution using several biophysical techniques and 
stabilizers were identified for each protein. The stability of the three antigens was then further 
characterized in the presence of the Alhydrogel aluminum hydroxide adjuvant. Techniques including 
intrinsic fluorescence, circular dichroism spectroscopy, and light scattering were used to monitor changes 
in the secondary and tertiary structure, and aggregation state of the three antigens as a function of pH and 
temperature. The complete data sets obtained using the various spectroscopic methods for each of the 
three proteins were combined in the form of EPDs to better visualize the data. SP1650 showed transition 
that represented changes at various levels of structure at about 55oC.  SP2216 proved to be a very unstable 
protein manifesting changes in its conformation even at room temperature. In contrast, SP1732 was seen 
to be very stable with little to no transition seen until about 70oC. Since SP1732 showed maximum 
stability at pH 5-6, and the other two antigens were stable in this pH range as well, the three antigens were 
formulated at pH 5.5 in a sodium acetate buffer. Excipient screening from a library of over 30 compounds 
revealed sorbitol, trehalose, lactose and sucrose as possible stabilizers for each of the three proteins. 
These sugars and sugar alcohols probably stabilize the three proteins in solution by the well documented 
mechanism of preferential hydration.14-16  Sodium chloride did not seem to have a significant effect on the 
physical stability of any of the three proteins; therefore, it was removed from the formulations to lower 
the osmolarity of the solution. The addition of 50 µM manganese chloride produced a dramatic increase 
in the stability of SP1650, so it was also included. Experiments with lower concentrations of manganese 
were not conducted. It may thus be possible to obtain a similar degree of stabilization by using the lower 
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concentrations of manganese. Additionally, zinc may also be evaluated in the future since the SP1650 
protein also binds to zinc as well as manganese.17  
Subunit vaccines are usually insufficiently immunogenic by themselves and therefore require an 
adjuvant. Common aluminum salt adjuvants such as Alhydrogel and Adjuphos are thought to be most 
effective with the antigen adsorbed on to the adjuvant surface, although this has been disputed and their 
mechanism of immunopotentiation is still under active investigation. 18-23 Alhydrogel demonstrated 
excellent binding properties to each of the three antigens. The addition of NaCl was not sufficient to 
desorb the protein from the surface of the adjuvant hinting that mechanisms other than simple 
electrostatic interactions may be at play. All of the proteins were tested for desorption using various 
agents after 30 minutes of adsorption. The differences in the desorption patterns are presumably due to 
the differences in structural characteristics of the three proteins. It is usually more difficult to desorb 
proteins if they are allowed to adsorb to the adjuvant for longer periods of time due to structural 
transitions as the bound proteins optimize their interactions with the surface. A common desorbing agent 
was not found for all the three proteins. This result could, in the future, pose some analytical difficulties 
while studying antigenicity or chemical degradation of the adsorbed antigens, although combinations of 
the agents found for the individual antigens might be effective. The conformational stability of the 
adsorbed antigens was studied using intrinsic fluorescence spectroscopy and fourier transform infrared 
spectroscopy. Tryptophan fluorescence spectroscopy revealed changes in tertiary structure, whereas 
infrared spectroscopy found alterations in protein secondary structure. Several earlier studies have shown 
that the protein antigens are often destabilized when adsorbed onto the adjuvant.21,24,25  In this work, 
SP1650 was found to be dramatically destabilized when adsorbed to Alhydrogel as seen by the lowering 
in the onset temperature of the protein’s structural transitions. This destabilizing effect was countered by 
the addition of 5 mM phosphate, which presumably converts some of the aluminum hydroxide to 
aluminum phosphate and thereby lowering the surface pH.26 The high surface pH of aluminum hydroxide 
may induce instability of the adsorbed proteins. The addition of 5 mM phosphate did not affect the 
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adsorption of the three antigens to Alhydrogel, although higher phosphate concentrations resulted in 
major losses in binding (data not shown). In contrast, SP1732 was stabilized on the surface of the 
adjuvant. The thermal transition that initiates at about 70oC for SP1732 in solution does not occur while it 
is adsorbed to the adjuvant.  FTIR was used to study the stability of SP2216 while adsorbed to the 
Alhydrogel due to the absence of intrinsic fluorescence. Changes in the second derivative peak intensity 
at 1620 cm-1 were monitored as a function of temperature. These changes presumably reflect alterations in 
the intermolecular beta sheet content of the protein. No significant changes in the stability of SP2216 
were observed when the protein was adsorbed to Alhydrogel. This effect might not be observed, however, 
if the protein structure was analyzed using a technique sensitive to changes in the tertiary structure of the 
protein.  
One potential concern in the development of the trivalent vaccine is the instability of SP2216 
protein component. Alterations in this protein antigen’s structural integrity were observed as initiating at 
room temperature. Although several stabilizers were identified that improve  the stability of the protein,  
given the relative instability of SP2216, there could be some benefit in removing this protein from the 
vaccine from a long term storage stability point of view. At this stage in development, however, SP2216 
is still included in the vaccine for examination in initial animal studies due to the degree of the 
conservation of the protein (~100%) in the different serotypes of S. pneumoniae. This potential utility of 
this antigen is especially important given the wide serotype variation in the developing world.  
 In conclusion, candidate formulations of a trivalent recombinant protein vaccine containing 
aluminum hydroxide adjuvant for protection against S. pneumoniae were identified based on a series of 
preformulation characterization studies as described above. Additives such as sorbitol, sucrose, and 
trehalose were observed to be good stabilizers for the three antigens at concentrations of 5-15% (w/v).  
The addition of 50 µM manganese also showed a large increase in physical stability of SP1650.  The 
addition of 5 mM phosphate greatly improved the physical stability of SP1650 on the adjuvant surface 
and may also help protect the proteins from deamidation, since proteins have been known to undergo 
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deamidation while adsorbed onto the surface of Alhydrogel due to the high local pH.26 The next stage of 
this vaccine formulation development work will require evaluation of immunogenicity data and chemical 
degradation studies during long term stability studies. A new set of analytical and stability problems will 
be encountered when the three proteins are actually combined together into a single trivalent vaccine. In 
particular, the possibility of interaction among the proteins will need to be critically examined. In the 
combination vaccine, it may be possible to separate the antigens and examine them individually, but 
analytical methods to test each of the protein antigens in the actual trivalent vaccine still need to be 
developed.  In addition, although aluminum salt adjuvants are the most commonly used adjuvants in 
current vaccines, additional or alternative adjuvants should be considered in the future to enhance both 
humoral and cellular immunity.    
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Introduction 
Vaccines are widely used in animals to prevent many kinds of diseases. Most of these vaccines 
were developed and stabilized empirically. Apart from a few exceptions such as the vaccines for rabies 
and lyme disease, newer technologies such as recombinantly produced proteins have not yet significantly 
penetrated the veterinary vaccine market.1 The most common vaccines used in veterinary medicine are 
based on live attenuated viruses and bacteria, due to their cost effectiveness, high immunogenicity and 
efficacy. Live attenuated viral strains, however, are not very stable during storage, resulting in short shelf 
lives as well as loss of potency when exposed to high temperatures.2 Due to severe requirements to 
minimize costs of veterinary vaccines, most viral vaccines are not fully characterized from a formulation 
point of view. The addition of certain low-cost stabilizers might be able to increase the stability of the 
viral components and thereby significantly increase the shelf life of such vaccines.  
A vaccine against three viruses that pose a serious threat to dogs and other animals is employed. 
These are the attenuated forms of the canine distemper virus (CDV), canine parainfluenza virus (CPI), 
and canine adeno virus type 2 (CAV2). Canine distemper is caused by the canine distemper virus, which 
is a paramyxovirus and is closely related to the measles virus.1,10,11 It is a highly contagious disease 
observed in dogs and other wildlife worldwide. Apart from dogs, the virus has been known to infect 
wolves, ferrets, and skunks among others10. Prior studies on the distemper virus indicate it to be very 
thermo-labile with over 50% loss in infectivity within 2 days of exposure to room temperatures12. The 
canine parainfluenza virus is another paramyxoviridae, and is a major cause of lower respiratory infection 
in dogs. Canine adenovirus type 2 is a non-enveloped virus and is thought it be a potential cause of kennel 
cough. The combination vaccine, DA2PPC, is currently a core vaccine for dogs administered at 8 weeks 
of age, with booster doses every year. DA2PPC is effective against the distemper, adenovirus type 2, 
parvovirus, parainfluenza virus and the canine corona virus.  
This work describes a simple cost effective empirical phase diagram-based approach towards the 
preformulation development of a trivalent live attenuated viral vaccine using biophysical techniques.3-9  
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The empirical phase diagram approach described in this paper has been successfully applied to the 
preformulation development of therapeutic proteins and vaccines, including antibodies, subunit proteins, 
viruses, and bacteria.3-9 The unique feature of this work is the demonstration that a multicomponent 
vaccine can be separated into its individual antigens, each stabilized and common stabilizers identified 
which should be effective in the multivalent vaccine.  
Materials and Methods 
	  
Frozen cell lysates containing the individual viruses, CDV, CPI and CAV2 were received from 
Merck Animal Health Inc. (Elkhorn, NE). The concentrations of the viruses after purification were 
determined using a BCA assay. All reagents used in this assay were purchased from Thermo Scientific 
(Rockford, IL). Citrate-phosphate (20 mM) buffers (pH 5.5, 6.0, 6.5, 7.0, 7.5 and 8.0) at a total ionic 
strength of 0.15 (adjusted with NaCl) were prepared using citric acid monohydrate (Fisher, Pittsburgh, 
PA) and sodium phosphate dibasic, anhydrous (Sigma, St. Louis, MO). All excipients were purchased 
from Sigma (St. Louis, MO) and were analytical grade.  
Purification 
Purification of Canine Distemper Virus (CDV) 
	  
The cell culture medium containing the virus was thawed for 24-36 hours at 4 oC. The medium was 
then centrifuged twice at 5,000xg for 20 minutes to pellet particulate matter and cell debris in a bench top 
centrifuge (Thermo Electron, Model: C5LR). The supernatant was then centrifuged at 40,000xg for two 
hours to pellet the virus using a Beckman Coulter Optimax ultracentrifuge equipped with a MLA-80 fixed 
angle rotor. The viral pellet was washed twice and re-suspended in a minimal amount of  20 mM citrate 
phosphate (CP) buffer containing 2.7% sucrose, pH 7 (I = 0.15). The solution was then filtered using a 0.4 
µm filter to remove any remaining viral aggregates that may have formed during the purification process. 
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The purified virus solution was then stored at 4 oC. All experiments were conducted within two days due 
to the instability of the virus.   
Purification of Canine Parainfluenza Virus (CPI) 
	  
The purification process for the canine parainfluenza virus (CPI) is similar to that for CDV. The cell 
culture medium was first subjected to same procedures as described above for the CDV. In addition, the 
filtered viral solution obtained is subjected to further purification using sucrose gradient centrifugation of 
20-50% (w/v) in 5% increments. Five hundred µL of each layer were added slowly to maintain the 
gradient.  The filtered viral solution was added to the top of the gradient, which was centrifuged at 
40,000xg for 17 hours at 4oC (Beckman Coulter OptimaMax Ultracentrifuge, MLS-50 swinging bucket 
rotor).  The 35-45% sucrose fractions were found to contain a majority of the viral material and were 
washed with ~10 mL of cold buffer and the virus was pelleted by centrifugation at 40,000xg for 3 hours at 
4oC.  The pellet was then re-suspended in a minimal amount of buffer to concentrate the viral material. 
The resulting viral solution was dialyzed against 20 mM CP buffer to remove any trace amount of 
sucrose.  
Purification of Canine Adeno Virus (CAV2) 
	  
The cell lysate containing CAV2 was centrifuged at 5,000xg for 25 min at 4 °C. The supernatant 
was separated and ammonium sulfate was added to the supernatant gradually until 40% saturation was 
reached. This was followed by a 2 hour incubation period. Precipitated virus samples were separated from 
the supernatant by centrifuging at 5,000xg for 25 min at 4 °C. The virus precipitate was then reconstituted 
and dialyzed against 20 mM CP buffer.  
Transmission Electron Microscopy (TEM) 
	  
Electron microscopy imaging of uranyl acetate-stained virus samples was performed to analyze 
potential visible structural alterations as a result of the purification process.  The virus samples were 
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subjected to the purification procedures described above and submitted to the Microscopy and Analytical 
Imaging Lab at the University of Kansas for TEM imaging.  The virus samples were subject to negative 
staining with uranyl acetate and imaging of the samples was performed with a Tecnai G2 transmission 
electron microscope (FEI Company, Hillsboro, OR). 
SDS-PAGE and Western blot 
	  
Virus samples were boiled for 10 minutes in sample buffer containing β-mercaptoethanol before 
loading onto the 4-12% precast gel (Invitrogen). 20 µL of virus sample was loaded in each well. A 150 V 
constant voltage was then passed through the gel until the bromophenol blue line marker reached the 
bottom of the gel. The resulting gel was then stained overnight using 0.1% Coomassie brilliant blue in 
10% glacial acetic acid solution. Destaining of the gel was then performed in a solution containing 10% 
methanol and 7% glacial acetic acid. Silver stain was used in the case of the canine distemper and canine 
parainfluenza viruses using a silver stain kit (Sigma Aldrich), and the standard protocol was followed. 
Western blots were performed to test for antigenic peptides from the canine distemper virus. Separated 
proteins in the gels were transferred to a nitrocellulose membrane electrophoretically at 100 V for 1 hour. 
The blotted membrane was then washed overnight at 4oC with the transfer buffer containing 5% milk and 
0.1% tween (w/v) to ensure no stray proteins adhere to the membrane. The membrane was then treated 
with the primary antibody, which was raised against the distemper virus in goats (Merck Animal Health 
Inc., Elkhorn, NE) for 2 hours at room temperature. The membrane was then washed with the transfer 
buffer containing 0.1% tween-20 for 5 minutes three times. The bound antibodies were then detected by 
horseradish peroxidase-conjugated anti-goat secondary antibody (Sigma Aldrich) treated with the 1-Step 
TMB blotting substrate solution (Thermo scientific). Adequate antibodies were not available for Western 
blot analysis of the other two viruses.  
Dynamic Light Scattering 
 The hydrodynamic diameter of the three viruses was analyzed using a Dynapro dynamic light 
scattering instrument (Wyatt Technology, Santa Barbara, CA)). The hydrodynamic diameter was 
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calculated from the diffusion coefficient by the Stokes-Einstein equation using the method of cumulants 
(intensity based). The temperature was maintained at 20oC and the pH at 7. Viscosity of the buffer was 
measured using a SVM-3000 Stabinger viscometer (Anton-Paar, Austria) and the DLS data was corrected 
for the viscosity as needed.  
Biophysical Characterization 
	  
Far-UV Circular Dichroism (CD) Spectroscopy  
CD spectra were acquired using a Jasco J-810 spectropolarimeter equipped with a 6-position 
peltier temperature controlled sample cell holder. CD spectra were obtained from 260-190 nm. Melting 
curves of the proteins were constructed by plotting the CD signal at 222 nm at a 2.5 oC interval between 
10 and 87.5 oC. In the excipient screening experiments, an Applied Photophysics Chirascan Plus 
spectropolarimeter (Leatherhead, UK) was employed to obtain the CD spectra. Experimental parameters 
such as the temperature range and interval times remained the same. 
Intrinsic Tryptophan (Trp) Fluorescence Spectroscopy and static light scattering 
Intrinsic fluorescence spectra were acquired using a Photon Technology International (PTI) 
spectrofluorometer (Lawrenceville, NJ) equipped with a turreted 4-position peltier-controlled cell holder. 
The Trp residues in the various viral proteins were excited at 295 nm, and the emission spectra were 
collected from 310 to 400 nm. Light scattering data were also collected at 295 nm using a second detector 
located at a 180o angle to the emission detector. Fluorescence spectra was collected every 2.5 oC from 10 
oC to 87.5 oC. Using Microcal Origin 7 software, peak positions and intensities of the emission spectra 
were obtained using a mean spectral center of mass method (msm) that shifts the actual peak positions by 
approximately 10-12 nm to the red, but produces better S/N ratios.  
Empirical Phase Diagrams (EPDs) 
CD molar ellipticity at 222 nm, intrinsic Trp fluorescence peak shifts, and static light scattering 
data sets were used in the construction of the empirical phase diagrams. Briefly, two indexes were 
constructed corresponding to the tertiary and secondary structures of the viral proteins. A third index was 
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constructed based on the aggregation propensity of the viral particles. These three indexes were reduced 
to RGB values and mapped as a function of pH and temperature to obtain the phase diagrams. Red 
represents the CD data, green the intrinsic fluorescence data and blue represents the protein association 
(aggregation) data. In addition, data obtained from the different measurements were normalized to 
account from slight differences in concentration of the virus, which arise from the different batches of 
purification.  
Excipient Screening 
Aggregation Assay (CAV2 and CDV) 
	  
Since CAV2 and CDV were both prone to aggregation in solution at elevated temperatures (see 
results section), an aggregation assay was used for high throughput screening of potential stabilizers for 
these two live viruses. A library of GRAS (Generally Regarded As Safe) compounds was screened for 
their ability to inhibit the aggregation propensity of the two viruses. The aggregation was monitored by 
optical density measurements at 350 nm using a 96-well plate reader (Spectra Max M5, Molecular 
Devices, Sunnyvale, CA). The aggregation assay was performed at 55 °C (at a concentration of 0.2 mg/ml 
for CAV2 and 0.5 mg/ml for CDV) in CP buffer. These conditions were selected based upon the apparent 
phase boundaries observed in the empirical phase diagrams. Virus sample was added to wells containing 
excipient(s) at the selected pH and incubated at 55 °C for 90 min for CAV2 and 180 minutes for CDV. 
The optical density was monitored at 350 nm (OD350) every 2 minutes. Samples of virus and buffer with 
excipient(s) (blanks) were examined simultaneously and served as controls. The measurements were 
corrected for intrinsic buffer-excipient effects by subtracting values of the blanks prior to data analysis. 
Each sample was evaluated in triplicate. Percent inhibition of aggregation was calculated employing the 
following expression: 
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where ∆OD350 (E) represents the change in OD350 during heating of the virus containing solution in the 
presence of the excipient and ∆OD350 (C) is the change in OD350 during heating of virus solution 
without excipient. 
Structural Stability Assay 
	  
Compounds which effectively inhibited aggregation of CDV and CAV2 were further investigated 
for their ability to protect and/or enhance the structural stability of the viruses. The structural stability of 
the viruses in the presence and absence of selected excipients was monitored by CD (thermal melts at 222 
nm) spectroscopy. Combinations of excipients at different concentrations were also studied for their 
ability to stabilize secondary structure of the viral proteins (CD) and to inhibit aggregation (OD350) at pH 
7.0. 
CPI Virus Excipient Screening 
	  
The CPI virus did not aggregate in solution at elevated temperatures; therefore, the aggregation 
assay described above was not performed.  Instead, intrinsic tryptophan fluorescence peak position 
measurements were used as an indication of any stabilization effects. 26 GRAS compounds in several 
variations of concentration and combinations were screened for their ability to increase the melting 
temperature of the CPI virus at 0.1 mg/mL.  The excipients were dissolved in the working buffer (20 mM 
CP buffer, I = 0.15 (NaCl), 2.71% sucrose, pH 7.0).  The working buffer for excipient screening was 
chosen on the basis of the apparent phase boundaries observed in the empirical phase diagrams and 
further experimental work.    
%	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Excipients effective for all three purified viruses were tested in combination once initial screening 
studies were completed.  A first derivative method using Microcal Origin 7.0 software was used to 
determine the transition melt temperature (Tm) of the virus in the presence of the different stabilizers.  All 
measurements were made within one week of thawing the purified sample to prevent aggregation of the 
virus over time. 
Results 
	  
Each of the three viruses was purified to obtain samples for biophysical characterization and 
stability assessment. The purified viral samples were first tested using electron microscopy, SDS-PAGE 
and western blot analysis to confirm the presence of intact viral material after purification. Figures 4.1A, 
4.1D and 4.2 outline the data obtained for the canine distemper virus (CDV). Figure 4.1A shows an TEM 
image of virus particles of about 100-150 nm in diameter, similar to images previously published.13 
Figure 4.1D shows the SDS-PAGE data for the crudely purified virus. The canine distemper virus 
consists of 7 proteins. The L (180kDa), H (80kDa) and P (70 kDa) proteins as well as the fusion proteins 
F0 and F1 (60 and 40 kDa), N (60 kDa), the Matrix (37kDa) and S proteins (15 kDa) were all present and 
their size correlates well with that observed in previous studies.14,15 Several additional bands were also 
observed, which suggests that not all impurities were removed using the purification process described 
above. Western blots were used to confirm the presence of antigenic canine distemper proteins using an 
antibody raised against the distemper virus. The western blot showed 2 bands corresponding to the matrix 
protein and another at 60 kDa, corresponding to the fusion protein F0 or the N protein (data not shown).   
Dynamic light scattering measurements showed an average diameter of approximately 200 nm for 
the CDV samples at pH 7.  Figure 4.2A shows the circular dichroism spectrum of the distemper virus at 
10 oC and pH 7. A major negative peak was observed at about 208 nm, with a shoulder near 220 nm, 
hinting at the presence of some α-helical structures in the viral proteins. Figure 4.2B shows the effect of 
temperature on the CD signal at 222 nm. Although no sharp structural transitions were seen at any of pH 
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conditions (5.5-8.0), a gradual transition, initiating at about 20 oC, is observed at all pH values. Figure 
4.2C shows the effect of temperature on the position of the fluorescence peak maxima of the viral proteins 
as a function of temperature. Broad transitions are seen at most pH values, except at pH 8 where a sharper 
transition initiates at about 50 oC. Changes in the emission peak maxima presumably reflect changes in 
the micro environment of the intrinsic (Trp) fluorophores, which in this case are the tryptophan residues 
in the various viral proteins. A red shift in the intrinsic fluorescence peak position maxima generally 
indicates the exposure of the apolar Trp residues to a more polar environment suggesting at least partial 
unfolding of the molecule (Figure 4.2C). Figure 4.2D shows the effect of temperature on the static light 
scattering intensity at different pH values. An initial decrease in the light scattering intensity was 
observed until 30 oC, followed by an increase in scattering intensity. The increase in the scatter intensity 
at about 35 oC is consistent with limited aggregation of the virus.  
The purification and biophysical characterization data for the canine parainfluenza virus are 
shown in Figures 4.1B, 4.1E and Figure 4.3, respectively. Figure 1B shows a TEM image of several intact 
CPI virions and their nucleocapsids. The 35% fraction from the sucrose gradient was run on an SDS-
PAGE gel (Figure 4.1E). This gel was compared to that of the human parainfluenza virus, due to lack of 
prior literature data on the canine parainfluenza virus.16 The bands corresponding to proteins L, HN, NP, 
F, P, A and M were all seen in the gel. Slight differences in their size were observed compared to that of 
the human parainfluenza virus presumably due to differences in protein sequences in the two viruses. 
Additional bands were observed apart from the major viral proteins indicative of the presence of some 
residual impurities. DLS measurements were also used to confirm the size of the purified virus.  The 
diameter of CPI was estimated to be about 270 nm, similar to reported values of 150-300 nm in diameter 
for the human parainfluenza virus.16 Overall, a significantly improved level of purification of the CPI 
virus from crude cell lysate was successful while maintaining intact enveloped virus. Figure 4.3A shows 
the circular dichroism spectrum for the CPI virus at 10 oC and pH 7. The CD spectrum shows a double 
minimum around 208 and 222 nm, indicating the presence of alpha helical structure in the viral proteins. 
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The CD melting curves at 222 nm for the CPI virus are shown in Figure 4.3B. No sudden changes in the 
ellipticity were noted with increasing temperature at any pH value. Instead, a continual decrease in CD 
signal initiating at room temperature was observed, indicating a gradual loss of secondary structure in the 
viral proteins. Figure 4.3C shows the change in the peak position of the emission maximum as a function 
of increasing temperature at different pH values. A small change in the peak position at all pH values was 
observed at about 45-50 oC.  The CPI virus was found to be most stable at pH 6 with the transition 
initiating at about 45oC. The small change in peak position seen at lower temperatures at other pH values 
was also not observed at pH 6. Static light scattering melts for the CPI virus are shown in Figure 4.3D. No 
significant increase in the static light scattering intensity was observed at any pH with increasing 
temperature, indicating no major aggregation events at increased temperature.  
The canine adenovirus type 2 (CAV2) was purified using ammonium sulfate precipitation. 
Figures 4.1C, 4.1F and Figure 4.4 show the purification and the biophysical characterization data for 
CAV2, respectively.  TEM images of CAV2 particles purified using ammonium sulfate precipitation are 
shown in Figure 4.1C. Several virions of about 80 nm are observed in the TEM image, similar to other 
values previously reported for adenoviruses.17 Figure 4.1F shows the SDS-PAGE gel for the purified 
CAV2. Multiple bands such as PII, PIII, PIIIA, and PV were observed closely matching the protein bands 
of CAV2 studied previously.18 The CD spectrum of CAV2 proteins at 10 °C and pH 7 displays a double 
minimum at approximately 208 and 222 nm (Figure 4.4A) which is again characteristic of high α-helical 
content. Changes in the CD signal at 222 nm upon heating were monitored for CAV2 (Figure 4.4B). The 
CD signal decreased with small transitions at all pH values indicating some loss in protein secondary 
structure upon heating. The midpoint of the thermal transitions occurs at lower temperatures for virus 
protein at low pH. The transition for the change in the CD signal initiates at about 30 oC at pH 6, and 
increases to about 40 oC at pH values of 7 to 8. The tertiary structure of the CAV2 was studied by 
measuring the peak shifts in Trp emission as a function of temperature (Figure 4.4C). A red shift was 
observed in the emission peak maxima beginning at  ~30 oC at each pH. Thus, the CAV2 proteins appear 
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to begin to unfold around 30 °C and undergo a transition with a Tm of approximately 55 °C. Static light 
scattering was employed to provide insight into the aggregation behavior of the CAV2 virus in solution. 
At pH 5.5, 6.0, CAV2 showed greater light scattering intensities even at low temperatures indicating the 
presence of some aggregation (Figure 4.4D). CAV2 undergoes further aggregation at these pH values 
with transitions starting as early as 30 °C. The sharp decrease in static light intensity seen after 75 °C may 
be due to precipitation of CAV2 aggregates. At pH 6.5 and 7.0, aggregation starts at ~ 42 °C as indicated 
by a sudden increase in static light scattering intensity. CAV2 shows biphasic transitions at pH 7.5 and 
8.0 with the first transition starting at ~45 °C and the second one at 65 °C.  
The biophysical characterization data for each of the three viruses were compiled to construct the 
empirical phase diagram (EPD) for each virus as shown in Figure 4.5. The empirical phase diagrams 
(EPDs) for CDV, CPI virus and CAV2 are shown in Figure 4.5A, 4.5B and 4.5C, respectively.  For the 
construction of the EPDs, data obtained using circular dichroism, static light scattering and intrinsic 
fluorescence spectroscopy were used with the red representing the CD (secondary structure), green the 
intrinsic fluorescence (tertiary structure), and blue representing the aggregation of the virus.  
The EPD for the canine distemper virus (CDV) is shown in Figure 4.5A. The CDV virus was 
identified as conformationally stable in region I between pH 6 and 8 at lower temperatures. The viral 
particles were found to be partially aggregated with its proteins altered in conformation at the lower pH 
values and at modestly elevated temperatures (region II).  Aggregation and unfolding of the viral proteins 
was observed at high temperatures at all pH values and is shown in region III. Figure 4.5B shows the EPD 
for the CPI virus. Region I appears to be the region where the CPI virus is most stable. Region II depicts a 
state of the CPI virus where the viral proteins are in their native state, but a slight swelling of the virus is 
caused by increasing temperature. Unfolding of the viral proteins was observed at region III. The 
unfolding of the CPI viral proteins along with possible aggregation is seen in region IV. The empirical 
phase diagram for CAV2 is shown in Figure 4.5C. The figure shows three distinct regions. Region I at 
temperature below 40 oC at all pH values is presumably the native form of the CAV2 virus. 
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Conformational changes in the CAV2 virus were observed in region II at pH values of 6.5 to 8 and 
around 55 oC. CAV2 tends to aggregate at all pH values at higher temperatures as seen in region III.  
A common solution pH of 7.0 was selected for further studies with each of the three viruses based 
on the apparent phase boundaries observed in their respective EPDs (Figure 4.5).  To examine the effects 
of different agents on the stability of the three individual viruses, a library of GRAS compounds including 
several sugars, sugar alcohols, surfactants, and amino acids among others was tested for stabilizing effects 
on the viruses. Screening for the canine distemper virus (CDV) and the canine adenovirus (CAV2) 
employed a kinetic based aggregation method in which the virus was incubated at 55oC in the presence of 
various compounds. Stabilizers of the canine parainfluenza virus (CPI) were identified using intrinsic Trp 
fluorescence spectroscopy since the virus did not aggregate significantly at the concentrations tested. 
Table 1 lists the different compounds tested along with the percent inhibition of aggregation for CDV and 
CAV2, along with the thermal unfolding (Tm) values in the case of the CPI virus. Figure 4.6A shows 
representative data from Table 1 in which the increase in optical density at 350 nm for CDV samples 
when incubated at 55 oC, was monitored as a function of time in the presence of selected stabilizers and 
destabilizers. An immediate increase in the optical density at 350 nm was observed in the case of 
destabilizers like diethanolamine and guanidine while no notable increases in the optical density were 
seen in the case of stabilizers such as sucrose and sorbitol. Similar results were observed for CAV2 as 
well with sucrose, sorbitol, dextrose and lysine inhibiting temperature induced aggregation (Table 1).  
Compounds that showed a positive effect on the inhibition of aggregation were selected to further 
study their effect on the stability of the three viruses. For this, circular dichroism spectroscopy was used 
to determine the effect of the selected compounds on stabilizing the secondary structure of the viral 
proteins.  Table 2 summarizes the thermal unfolding values for each of the three viruses at different 
concentrations of sucrose and sorbitol. Figure 4.6C shows the effect of increasing the concentration of 
sorbitol on the CD signal at 222 nm of the CDV virus. Maximum stabilization effects were seen in the 
samples containing the highest concentrations of sorbitol.  Sorbitol at concentrations of 25% showed no 
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major signal changes in the circular dichroism signal up to about 40 oC. The same was found to be true in 
the case of sucrose and trehalose as well. For the CPI virus, Figure 4.6B shows the intrinsic fluorescence 
melts in the presence of various selected stabilizers and destabilizers. Tm values were calculated from the 
first derivative of the peak position melting curves as shown in Figure 4.6D. Again, sugars and sugar 
alcohols showed promising stabilizing properties with increases in the thermal unfolding (Tm) values of 
about 5oC. Similar to the CDV and CAV2, the maximum stabilization of the CPI virus was achieved at 
the highest concentrations of sorbitol and sucrose tested as seen in Table 2.  
In summary, sorbitol and sucrose proved to be common stabilizers for all three viruses. Some 
stabilizers such as trehalose and proline had positive effects on CDV and the CPI virus, but negative 
effects on CAV2. Sorbitol at concentration of 25% (w/v) proved to be most effective at stabilizing the 
viruses individually from aggregation and the viral proteins from temperature induced conformational 
changes.  
Discussion 
	  
  The purification procedure for each of the three viruses yielded viral samples of sufficient 
purity to enable their individual biophysical characterization. The EM images of the three viruses show 
primarily intact viral particles. Dynamic light scattering also finds the size of viral particles are in line 
with previously published data. SDS-PAGE gels showed several bands for each virus corresponding to 
the known molecular weight of the viral proteins. Western blot experiments of the canine distemper virus 
showed two bands corresponding to the matrix protein, and the fusion (F0) or the neuramidase (N) 
protein. Western blot data for the other two viruses were not available due to the lack of adequate primary 
antibodies.  
 The biophysical characterization of the three viruses was performed individually using circular 
dichroism and intrinsic fluorescence spectroscopy, and static light scattering experiments. Circular 
dichroism and fluorescence spectroscopy were used to study changes in different levels of structure 
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(secondary and tertiary) of the viral proteins while static light scattering experiments analyzed the 
aggregational propensity of the viruses. Although the results reflect the sum of the effects of temperature 
and pH on all the proteins in each virus, they still serve as a useful measure of the overall stability of the 
virus even if their effects on individual viral proteins cannot be resolved. Stabilizers which were capable 
of enhancing the aggregational stability and the conformational stability for all the three viruses were 
identified.  
 The data obtained from circular dichroism spectroscopy, intrinsic fluorescence spectroscopy and 
static light scattering were combined in the form of a three-index empirical phase diagram to better 
understand the effect of temperature and pH on the gross structure of the viruses. The empirical phase 
diagrams for each of the viruses indicate that each virus is very thermo-labile. Changes in the distemper 
virus were seen initiating at about 30oC, with the CDV virus aggregating at around 45oC. The canine 
parainfluenza virus was found to be even more sensitive to temperature with changes initiating below 
room temperature. Partial unfolding of the viral proteins was observed at about 50oC with the CPI virus 
aggregating at about 65oC. Of the three virus, the CAV2 proved to be the most resistant to temperature 
induced changes by maintaining its native state to about 45oC at pH 6.5-7.5. Aggregation of this virus was 
observed only at about 70oC over this pH range. CAV2 was observed to be more unstable at lower pH, 
with aggregation occurring as low as 40oC at pH 5.5 and 6. It is important to note that CAV2 is a non-
enveloped virus, which may account for some of the observed differences in stability.   
CDV and CAV2 viruses were prone to aggregation at elevated temperature and therefore, a 
kinetic based aggregation assay was employed to screen for potential stabilizers. Circular dichroism was 
further used to study the effect of the potential stabilizers on the secondary structure of the viral proteins 
from these two viruses. Screening of over 30 GRAS excipients yielded several common stabilizers such 
as sucrose, sorbitol, and lysine among others. These stabilizers were able to not only prevent these viruses 
from aggregating, but to also provide structural stability to the viral proteins. Several of excipients, 
however, such as dextran sulfate, were not able to conformationally stabilize the structure of the viral 
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proteins even though they inhibited aggregation (Table 1). Based on these data, a vaccine consisting of 
the above mentioned attenuated viruses should therefore benefit from the addition of stabilizers such as 
sucrose or sorbitol. Sucrose and sorbitol probably stabilize the viral particles by non-specific processes 
such as the well documented preferential hydration mechanism.19-21 Specific interactions should not be 
ruled out, however, since sialic acid, which is the natural ligand of the hemagglutinin (or the 
hemagglutinin-neuraminidase) protein in the distemper and the parainfluenza virus, bears some structural 
resemblance to stabilizing sugars. The amount of sucrose and/or sorbitol that can be added to the 
formulation may be limited by solution osmolarity.  For example, the osmolarity of a formulation must be 
considered due to the potential for pain and discomfort at the site of injection. Cell lysis has also been 
shown to occur with the use of formulation with high osmolarity values. Higher values than those used in 
humans may potentially be usable in these animal vaccines. 
When the three live attenuated viruses are mixed together to make a trivalent vaccine, the 
possibility of the viruses interacting with each other should be examined carefully. The lack of analytical 
assays at this point to probe the different viruses individually in the mixture makes it impossible to study 
each of the three viruses simultaneously. Therefore, it may be necessary to develop chromatographic 
separations to examine the biophysical properties of the individual viruses from the trivalent mixture.   
Ultimately, in vitro cell-based and animal potency studies will be necessary to decide on the best 
formulation and dosage criteria for this trivalent live virus vaccine. Additionally, spray drying or freeze 
drying of the final formulation may be performed to further stabilize the three live viruses during long 
term storage.  
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Conclusions 
 Over the past couple of decades, the pharmaceutical industry has tried to move away from 
traditional whole organism-based vaccines to sub-unit protein-based vaccines. There are several 
advantages to this such as increases in stability, better molecular definition and ease of manufacturing. 
There are, however, some drawbacks as well which include the low immunogenicity associated with sub-
unit protein vaccines. Despite this, there are several sub-unit vaccines on the market today, and several 
more being developed. In the last three chapters, I have described the formulation development of three 
vaccines: a protein subunit influenza vaccine, a trivalent subunit pneumococcal vaccine and a trivalent 
live attenuated viral vaccine against three canine viruses.  
 In chapter 2, I discussed the development of a protein subunit vaccine towards the 2009 pandemic 
H1N1 flu strain of swine origin utilizing the hemagglutinin surface antigen.  One of the major problems 
we encounter with influenza vaccines is the time involved with their development. Presently, it takes 
about 9 months to develop a seasonal influenza vaccine. In the event of a pandemic, thousands of lives 
may be lost in this time period.  By recombinantly producing the hemagglutinin antigen in tobacco plants, 
we should be able to significantly speed up the manufacturing process. Additionally, we may be able to 
identity formulation conditions of the vaccine within a few weeks using the empirical phase diagram 
approach. This was done using several biophysical techniques such as circular dichroism, intrinsic and 
extrinsic fluorescence spectroscopy and light scattering. Each of these techniques is used to study a 
different aspect of protein structure. From the initial characterization studies, HAC1 was found to be most 
stable at pH 7 and 8 and at temperature below 40oC.  It was also established that HAC1 was found to be 
in a conformationally altered state at lower pH values. These pH-dependent changes in conformation are 
fairly common with many viral surface antigens undergoing pH dependent conformational changes which 
help the virus infect their host cells.  
Since HAC1 was found to be most stable at pH 7, it was formulated in a 20mM imidazole buffer 
to screen for excipients. Intrinsic fluorescence spectroscopy was used to screen for stabilizers from a 
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library of GRAS compounds.  Traditionally used kinetic based aggregation assays were not used in this 
case since HAC1 did not aggregate significantly at acceptable temperatures. Sucrose, sorbitol, trehalose 
and other sugars and sugar alcohols proved to be to most promising stabilizers. These compounds were 
able to stabilize HAC1 conformationally as well as inhibit aggregation. Surfactants such as polysorbate-
20 and polysorbate-80 also were efficient in protecting the protein against aggregation. The 
concentrations of these potential stabilizers were optimized to determine if they can impart similar 
stabilizing effects at lower concentrations. The increase in thermal stability was found to be concentration 
dependent for stabilizers tested. Additionally, combinations of these stabilizers were tested to check for 
additive or synergistic effects. Only slight increases in thermal stability were observed when 
combinations of stabilizers were tested. Based on the increase in thermal stability of the protein and the 
required osmolarity of the formulations, 15% sorbitol, 10% sorbitol with 5% sucrose and 10% dextrose 
were chosen as the most ideal formulations for HAC1 in solution.  
The addition of aluminum salt adjuvants was also tested to boost the immunogenicity of vaccine. 
HAC1 showed high binding affinity towards Alhydrogel. One hundred micrograms of Alhydrogel was 
able to adsorb up to 160ug of HAC1. Saturation of the binding of HAC1 to Alhydrogel was not achieved 
over the concentration range examined. It was also found to be difficult to desorb HAC1 from the surface 
of the adjuvant. Such desorption of the antigen from the adjuvant may be important to search for possible 
chemical degradation of the protein during storage. A combination of 1M citrate and 2M urea was 
identified as a possible desorption agent because it was able to desorb over 80% of the adsorbed protein. 
The conformational stability of the protein was found to be affected by adsorption to the adjuvant. This 
appears to be the result of an optimization of the protein’s conformation on the adjuvants surface in order 
to reduce its free energy. Many of the stabilizers such as sorbitol and sucrose, which were identified as 
stabilizing the protein in solution also helped to stabilize the protein on the adjuvant surface. This, 
however, was not to the same extent as that observed in solution. The addition of 5mM sodium phosphate 
helped improve the stability of the adsorbed HAC1.  No significant desorption of the HAC1 from the 
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adjuvant was observed in the presence of any of the stabilizers. In addition to excipients, the effect of heat 
treatment or “annealing” was tested to see if any increase in stability could be obtained.  No significant 
conformational changes were observed until when HAC1 was exposed to temperatures of 40oC for 10 
minutes. Therefore, three formulations were found to stabilize HAC1 in the presence of the adjuvant. 
These were 15% sorbitol with 5mM phosphate and 0.01% tween-80, 5mM phosphate alone and HAC1 
annealed at 40oC.  
These formulations, along with the recommended solution formulations were tested in mice to see 
which produced the highest antibody titer. As expected, the formulations with Alhydrogel produced the 
greatest antibody response. It was also observed that 0.5mg/ml Alhydrogel was sufficient to elicit this 
antibody response. Among the non-adjuvanted formulations, 15% sorbitol showed the highest antibody 
titers. A more thorough study will be required to test for any differences observed in the use of the 
different excipients.  This vaccine was entered into phase I human trials in September 2010, which were 
completed in May 2011. HAC1 was found be safe and well tolerated at all dosage levels, with and 
without adjuvant. Preliminary reports suggest the immune response was highest in presence of the 
adjuvant. 
 Chapter 3 discusses the development of a trivalent protein sub-unit vaccine against S. 
pneumoniae. One of the major problems faced with this bacterium is its wide serotype distribution, which 
makes it hard to develop a single effective vaccine that could be used worldwide. In chapter 3, we 
explored the formulation development of three protein antigens – SP1650, SP1732 and SP2216. Varying 
stability profiles were observed for each of the three antigens. SP1732 was seen to be very stable, with no 
conformational differences observed until 70oC. SP1650 was relatively unstable, showing protein 
conformational changes and aggregation at about 45oC. SP2216 was found to be very unstable with 
conformational changes occurring below room temperature. These stability profiles were reflected in the 
empirical phase diagrams produced for each of the three proteins.  
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In a manner similar to HAC1, the three proteins were screened for stabilizers from a library of 
GRAS compounds. During this process the proteins were dialyzed into a 10mM sodium acetate buffer 
containing 150 mM NaCl and 0.067% tween-20 at pH 5.5. This buffer was identified by our collaborators 
at Intercell AG previously for the three antigens. Sorbitol and sucrose, along with other sugars and sugar-
alcohols were identified as potential common stabilizers for all three proteins. Manganese chloride was 
also able to significantly stabilize SP1650. The presence of manganese was able to increase the thermal 
transition temperature ofSP1650 by almost 15oC. The concentrations of these potential excipients were 
optimized to lower the osmolarity of the formulations. These stabilizers were also tested in combinations 
to search for additive or synergistic effects. Only the excipients that were able to stabilize all three 
proteins independently and simultaneously were chosen since all three antigens will be formulated 
together in a trivalent vaccine. The presence or absence of NaCl did not significantly affect the thermal 
transition temperatures of any of the three proteins, although a decreased extent of unfolding was 
observed in the case of SP1650. Five percent sorbitol with 10% trehalose, 10% trehalose and 5% sorbitol 
were identified as perspective stabilizers for the top three formulations recommended for the trivalent 
vaccine. In addition, 50um manganese chloride was recommended for the combined formulations due to 
its ability to drastically stabilize SP1650. NaCl was not included in the list of recommended components 
for the trivalent vaccine. This also helped lower the osmolarity of the formulations.  
All three antigens showed high affinity towards Alhydrogel, even though the pI of the three 
proteins is on either side of the formulation pH. This suggests that there may be other mechanisms 
affecting the adsorption process apart from simple electrostatic interactions. The three antigens bound 
weakly to Adjuphos with less than 60% of the total antigen binding. Near-saturation of binding to 
Alhydrogel of each antigen was observed in the adsorption isotherms. 50ug of Alhydrogel was able to 
adsorbed almost 90ug of each antigen.  The final dosage form is expected to contain about 50ug of each 
antigen in 600ug of Alhydrogel. At these concentrations, each of the three proteins should be completely 
bound to the adjuvant. A common desorption agent was not identified for all the proteins. Two molar 
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guanidine, however, was able to desorb over 80% of SP2216 and SP1732 from Alhydrogel. Similar levels 
of desorption of SP1650 required the use of a combination of 1M urea and 2M sodium citrate. The three 
antigens displayed different stability profiles when adsorbed on to the adjuvant. SP1650 was dramatically 
destabilized. This destabilization was partially offset by the addition of sodium phosphate at a 
concentration of 5mM. The secondary structure of SP2216 was found not to be perturbed when adsorbed 
on to the adjuvant as assessed by FTIR spectroscopy. On the other hand, SP1732 was found to be 
stabilized by its adsorption on to Alhydrogel as observed by temperature dependent intrinsic tryptophan 
fluorescence spectroscopy. This illustrates that the stability profile of the antigens while adsorbed to the 
adjuvant tends to be antigen specific.  
 When these three antigens are eventually combined to make a trivalent vaccine, the possibility of 
interaction between the three antigens needs to be explored. Due to a lack of assays to explore this aspect 
at this time, efforts are being undertaken to identify and develop assays that can be used to study all three 
antigens simultaneously. Additionally, animal studies are yet to be completed using the trivalent vaccine. 
These studies are on scheduled to be undertaken in 2013 by PATH.  
 The empirical phase diagram approach used to formulate the previous two vaccines was also used 
to formulate a trivalent live attenuated viral vaccine. This vaccine consists of attenuated forms of the 
canine distemper virus, canine parainfluenza virus and the canine adenovirus type 2. Each of the three 
viruses was purified to the maximum possible extent to enable an exploration of the biophysical 
properties of the three viruses. Canine adenovirus was purified using ammonium sulfate precipitation. 
The other two viruses were purified using ultracentrifugation. Additionally, a sucrose gradient was also 
employed in the case of the canine parainfluenza virus for further purification. Due to severe aggregation 
of the virus at low pH, the empirical phase diagrams for all three viruses was constructed between pH 
range of 5.5 to 8, at 0.5 pH unit intervals. Since all three viruses were most stable at about pH 7, a citrate 
phosphate buffer at pH 7 with 150mM NaCl was employed for further excipient screening studies. Again, 
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only the excipients that were able to stabilize all the three viruses were selected. Sorbitol and sucrose 
proved to be the most potent stabilizers of all three viruses.  
Because osmolarity of the formulation is less of a concern in animal vaccines, concentrations of 
stabilizers were increased to as much as 25% w/v in some cases. It was recommended that the cell lysates 
of the three viruses be combined in the presence of high concentrations of these stabilizing sugars. These 
studies illustrate the important result that the EPD approach is useable even in the case of complex 
molecular entities such as viruses. This may be at least partially due to the dominance of their physical 
properties by only one or a few proteins which are sensitive to the immunogenicity of the virus.  
 Further studies on this vaccine were performed by Intervet Inc., and improvements over previous 
commercial formulations have yielded over a year of viral stability and activity in solution. This may 
enable the use of solution vaccines in addition to the currently marketed freeze dried form, which requires 
reconstitution prior to administration of the vaccine.  
 With the experience gained with the formulation development of several vaccines, I would like to 
highlight a couple of areas where focus would be required to obtain a more ideal formulation. A third of 
all proteins contain a metal binding site. The presence of the metal ion can, in many cases, dramatically 
increase the thermal stability of the protein. An easy and obvious pathway to identify potential metals that 
can stabilize a protein therapeutic would be to screen each metal individually. This can sometimes be 
quite tedious and time consuming. It is possible to predict metal binding sites by several algorithms 
available online. Additionally, it may also be worthwhile to search for known proteins with similar 
sequences to identify potential metal binding sites.  
 Another aspect to consider is the osmolality of vaccine formulations. Once developed, these 
vaccines will be injected in millions of children and adults across the world. If these administrations have 
high osmolarity, they can cause pain and discomfort at the site of injection. Cell lysis has also been 
known to occur under such conditions. An effective formulation strategy that considers osmotic effects 
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can help lower such harmful side effects, while maximizing stability and immunogenicity. For instance, 
the removal of sodium chloride greatly reduced the osmolarity of the formulation of the trivalent 
recombinant protein based pneumococcal vaccine. The osmolarity reduced by the removal of sodium 
chloride may be replaced with suitable concentrations of a stabilizer to further increase stability of the 
vaccine.  
 Many of the vaccines developed today are multivalent. They have more than one component to 
produce a broad immunogenic response. Unfortunately, this can lead to interactions between the multiple 
components in the vaccine. When multivalent vaccines such as the live attenuated viral vaccine or the 
trivalent recombinant protein based pneumococcal vaccine are developed, it is important to consider and 
characterize the interactions between the various components of the vaccine and alter formulations to 
decrease such interactions if they are undesirable. 
 As more recombinant protein based vaccines continue to be developed, novel adjuvants are being 
identified. The aluminum salt adjuvants prevalent today may not be the ideal adjuvants for future or 
current vaccines. With each novel adjuvant, the formulation approach will need to be molded to best 
characterize the interactions between the adjuvants and the antigens and to optimize such effects. 
Future Studies 
 
 In case of each of the three vaccines formulations developed, there are several studies yet to be 
completed before work can continue further. These future studies have been discussed for each project. 
For the influenza vaccine, the animal studies showed high antibody titer in the presence of Alhydrogel. 
Initial phase I clinical trials showed the vaccine was safe in all doses tested. Currently phase II clinical 
trials are underway to establish the efficacy of the vaccine. Results from this study should be available 
within the next year. Phase III clinical trials for the vaccine still need to be initiated. In addition, the 
effects of newer adjuvants should be tested to determine if the vaccine can be made more immunogenic.  
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The trivalent pneumococcal vaccine has yet to be tested in an animal model. Upon successful 
completion of initial animal studies, the vaccine will then need to be subjected to clinical trials in which 
its safety and efficacy will be tested in humans. Also, with the presence three individual proteins in the 
vaccine, the potential for interactions between the proteins need to be studied. This was not performed in 
this study due to a lack of assays to explore these aspects. Such assays are, however, being currently 
developed.  
The trivalent live attenuated viral vaccine has been proven to be stable and active for over a year. 
Since this is not a human vaccine, extensive clinical trials need not be undertaken. Their efficacy in 
protecting dogs against the different diseases is being studied currently.   
In conclusion, the biophysical EPD-based approach described in this thesis is shown to be both 
efficient and effective methodology for characterization and stabilization for a variety of different 
vaccines. Although it continues to be refined, it currently offers an important addition to the tool kit of 
vaccine formulation development.  
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Tables 
 
Table 1.1: The effects of vaccines have had on the number of deaths caused by several deadly diseases in 
the United States. 
Disease Number of deaths 
  Before Vaccine After Vaccine 
Paralytic Polio 30,000 0 
Rubella 100,000 10 
Pertusis 100,000 <10,000 
Mumps 100,000 100 
Measles 1,000,000 10 
Diptehria 100,000 0 
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Table 1.2: Different types of vaccines elicit different types of immune response.  
Vaccine Type  
Type of Immune 
Response 
Diphteria Toxoid Toxoid Humoral 
Hepatitis A Killed Humoral 
Hepatitis B VLP Humoral 
Influenza Subunit Humoral 
Measles Live Attenuated - Viral Humoral + Cellular 
Mumps Live Attenuated - Viral Humoral + Cellular 
HPV  VLP Humoral 
Pneumoccal PS Subunit Conjugate Humoral 
Polio Killed Humoral 
Rabies Killed Humoral 
Rubella Live Attenuated - viral Humoral 
TB ( BCG) Live Attenuated - Bacterial Humoral + Cellular 
Varicella Live Attenuated - Viral Humoral + Cellular 
 
 
 
 
 
 
 
 
 
 
 
97	  
	  
Table 1.3: Selected marketed vaccines that contain aluminum salt adjuvants along with their dosages. 
AAHS is a proprietary aluminum salt adjuvant manufactured by Merck.  
Trade name Vaccine Adjuvant  Al per dose 
Daptacel Diphteria, Tetanus and pertusis Adjuphos 0.33 
Prevnar Pneumoccoccal 7-Valent Adjuphos 0.125 
Biothrax Antrax Alhydrogel 0.6 
Gardasil HPV AAHS 0.225 
Twinrix Hep A Alhydrogel and Adjuphos 0.45 
Recombivax HB Hep B AAHS 0.5 
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Table 2.1.  Effect of GRAS compounds on the conformational stability (Tm-Trp) and 
aggregation (Tm-SLS) of HAC1 as determined by intrinsic fluorescence and static light 
scattering. The effect of each compound on the aggregation and conformational stability of the 
protein is represented as a change in Tm. Compounds that inhibit aggregation and enhance 
stability have increased Tm values, while compounds that induce aggregation and reduce 
conformational stability  produced decreased Tm values. 
 
Excipient Tm (°C)-Trp Excipient Tm (°C)-SLS 
HAC1 53.9 HAC1 57.0 
20% Dextrose 58.2 0.1% Tween 80 64.0 
20% Sorbitol 58.1 20% Dextrose 63.5 
20% Sucrose 57.1 20% Sorbitol 62.8 
20% Glycerol 56.5 20% Sucrose 61.0 
20% Lactose 56.2 0.3M Lysine 60.0 
0.15M Malic Acid 55.3 20% Glycerol 60.0 
0.1% Tween 80 55.0 20% Lactose 59.9 
20% Trehalose 54.8 0.15M Lactic Acid 59.8 
0.2M Sodium Citrate 54.1 0.1% Pluronic F-68  58.9 
0.3M Lysine 53.9 0.1% Tween 20 58.5 
0.3M Glysine 53.8 5% γ-cyclodextrin 58.0 
0.15M Lactic Acid 53.6 0.15M Glutamic Acid 57.9 
0.1% Pluronic F-68  53.6 0.1% Brij 35 57.9 
5% γ-cyclodextrin 53.2 0.07M Aspartic Acid 57.5 
0.15M Glutamic Acid 53.2 2.5% α-cyclodextrin 57.5 
0.3M Proline 53.1 5% β-cyclodextrin 57.5 
0.1% Tween 20 53.0 20% Trehalose 57.5 
0.1% Brij 35 53.0 0.3M Diethanol Amine 57.1 
0.07M Aspartic Acid 53.0 0.3M Arginine 57.0 
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2.5% α-cyclodextrin 53.0 0.3M Glysine 56.1 
0.015M Calcium Chloride 52.7 0.3M Proline 56.0 
5% β-cyclodextrin 52.3 0.15M Malic Acid 55.2 
0.3M Diethanol Amine 51.5 7.5E-6M Dextran Sulfate 55.0 
0.3M Arginine 51.5 0.2M Sodium Citrate 55.0 
7.5E-6M Dextran Sulfate 50.8 0.015M Calcium Chloride 53.8 
0.3M Guanidine 49.0 0.3M Guanidine 53.1 
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Table 2.2. Effect of the concentration of selected GRAS compounds on the aggregation (Tm-
SLS) and the conformational stability (Tm-Trp) of HAC1 as determined by intrinsic fluorescence 
and static light scattering. 
 
Excipient Tm (°C)-Trp * Excipient Tm (°C) –SLS * 
HAC1 54.6 HAC1 54.5 
20% Sorbitol 59 20% Sorbitol 58.5 
15% Sorbitol  57.8 15% Sorbitol 58.9 
10% Sorbitol 56.9 10% Sorbitol 56.9 
20% Dextrose  58.9 20% Dextrose 62.8 
15%Dextrose  57.3 15% Dextrose 61 
10% Dextrose  57 10% Dextrose 60 
20% Sucrose  58.1 20% Sucrose 59.9 
15% Sucrose 56.2 15% Sucrose 59 
10% Sucrose 55.5 10% Sucrose 57.5 
20% Glycerol  57.4 20% Glycerol 59 
15% Glycerol 56.6 15% Glycerol 58.5 
10% Glycerol 57 10% Glycerol 59.5 
0.1% Tween-80  55 0.1% Tween-80  64 
0.05% Tween-80  53.6 0.05% Tween-80  57.4 
0.01% Tween-80  53.2 0.01% Tween-80  62 
  
* The precision of these values is estimated to be ±0.5oC based on two independent 
measurements. 
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Table 2.3. The effect of combinations of stabilizing GRAS compounds on the aggregation (a) 
and the conformational stability (b) of HAC1 as determined by intrinsic fluorescence and static 
light scattering.  
 
(a) 
Excipient Concentration Excipient  Concentration Tm (oC) –SLS* 
Sucrose 15% Tween-80 0.05% 61 
Dextrose 10% Glycerol 5% 60.8 
Dextrose 10% Sorbitol 5% 60.5 
Glycerol 10% Sucrose 5% 59.8 
Sorbitol 10% Sucrose 5% 58.9 
Sorbitol 15% Tween-80 0.05% 58.5 
 
(b) 
Excipient Concentration Excipient  Concentration Tm (oC)-Trp* 
Dextrose 10% Glycerol 5% 57.6 
Dextrose 10% Sorbitol 5% 57.2 
Sorbitol 10% Sucrose 5% 56.8 
Glycerol 10% Sucrose 5% 56.5 
Sucrose 15% Tween-80 0.05% 56.5 
Sorbitol 15% Tween-80 0.05% 54.5 
 
* The precision of these values is estimated to be ±0.5oC based on two independent 
measurements. 
 
 
 
 
102	  
	  
Table 2.4. Formulations tested in mouse immunogenicity study 
 
* 18 µg/dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Antigen Buffer Components Alhydrogel® 
1 
HAC1*  10 mM imidazole,  
150 mM NaCl, 
pH 7.0 
15% sorbitol 
None 2 10% sorbitol, 5% sucrose 
3 10% dextrose 
4 15% sorbitol, 0.01% Tween-80, 5 mM phosphate 
0.5 mg/ml of 
aluminum 5 5 mM phosphate 
6 HAC1* treated at 40 °C None 
7 HAC1* Saline None 1.8 mg/ml of 
aluminum 8 NA Saline None 
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Table 2.5. Mean HAI antibody titers and seropositive rates 
Group  1 2 3 4 5 6 7 8 
Mean ± SE* 
Day 
35 
304 ± 
138 26 ± 6 
154 ± 
68 
576 ± 
288 
800 ± 
214 
320 ± 
88 
800 ± 
214 
10 ± 
0 
% 
responders** 100 40 80 100 100 100 100 0 
Mean ± SE* 
Day 
70 
130 ± 
53 30 ± 6 46 ± 15 
704 ± 
251 
960 ± 
202 
640 ± 
263 
1280 ± 
0 
10 ± 
0 
% 
responders** 80 40 60 100 100 100 100 0 
 
* Mean HAI titers (± standard error) on day 35 or 70 (post second vaccination) 
** % animals with HAI titers ≥40 on day 35 or 70 (post second vaccination) 
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Table 3.1: Thermal unfolding temperature (Tm) values for SP1650 in the presence of various stabilizers 
and destabilizers in a 10mM sodium acetate buffer at pH 5.5. 
 
Excipient Tm (°C) 
Protein  59.1 
50 µM Manganese Chloride 70.0 
20% Lactose 68.4 
20% Dextrose  66.5 
0.2 M Sodium Citrate 64.0 
20% Trehalose 63.1 
20% Sorbitol 62.2 
20% Sucrose 62.2 
10% Mannitol 61.6 
0.3 M Glycine 61.0 
20% Glycerol 60.0 
0.15 M Glutamic Acid 60.0 
5% 2-OH propyl γ-cyclodextrin 59.9 
7.5E-6 M Dextran T70 59.5 
0.3 M Proline 59.3 
0.015 M Calcium Chloride 59.3 
0.07 M Aspartic Acid 59.2 
0.15 M Lactic Acid 59.2 
5% 2-OH propyl β-cyclodextrin 56.4 
0.3 M Histidine 55.1 
7.5E-6 M Dextran Sulfate 55.0 
0.3 M Diethanolamine 54.3 
0.3 M Arginine 51.5 
0.3 M Guanidine 51.5 
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Table 3.2: Thermal unfolding temperature (Tm)  values for SP1650 in the presence of selected stabilizers 
at various concentrations in a 10mM sodium acetate buffer at pH 5.5. Duplicate measurements were made 
for all combinations. The standard error was calculated to be below ± 0.5oC.   
 
Excipient Concentration Tm (oC) 
SP1650   59.1 
Sodium Citrate 0.05 M 60.1 
  0.1 M 60.7 
  0.15 M 62.5 
  0.2 M 63.9 
      
Lactose 5% 59.8 
  10% 61.3 
  15% 62.5 
  20% 67.6 
      
Sorbitol 5% 60.4 
  10% 62.0 
  15% 63.9 
  20% 66.0 
      
Trehalose 5% 60.0 
  10% 60.9 
  15% 61.5 
  20% 63.2 
      
Sucrose 5% 58.4 
  10% 59.3 
  15% 60.1 
  20% 62.2 
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Table 3.3: Thermal unfolding temperature (Tm)  values for three protein antigens (SP1650, SP1732 and 
SP2216) in the presence of selected stabilizers in a 10mM sodium acetate buffer at pH 5.5. *Reproducible 
transitions were not available for SP1732 in the presence of arginine 
 
Excipient SP1650  Tm (°C) 
SP1732  
Tonset (°C) 
SP2216  
Tm (°C) 
Protein  59.1 70.0 33.8 
50 µM Manganese Chloride 70.0 70.0 33.8 
20% Lactose 68.4 72.5 44.3 
20% Dextrose  66.5 72.5 43.3 
0.2 M Sodium Citrate 64.0 67.5 33.3 
20% Trehalose 63.1 72.5 42.2 
20% Sorbitol 62.2 72.5 42.6 
20% Sucrose 62.2 72.5 38.8 
10% Mannitol 61.6 72.5 38.0 
7.5E-6 M Dextran Sulfate 55.0 60.0 32.5 
0.3 M Dietanolamine 54.3 65.0 31.2 
0.3 M Arginine 51.5 NT* 27.0 
0.3 M Guanidine 51.5 70.0 25.5 
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Table 4.1:   The effect of different GRAS compounds on the physical stability of three purified 
live attenuated canine viruses.  The ability to inhibit aggregation of the canine distemper virus 
(CDV) and the canine adenovirus (CAV2) was measured in a 20 mM citrate phosphate buffer at 
pH 7. Standard error was calculated to be ±5% based on three individual experiments for the 
CDV and CAV2. The thermal unfolding temperature (Tm) values for CPI virus in the presence 
of different excipients were measured by intrinsic fluorescence spectroscopy with the precision 
of the data on the order of ±0.5oC. ND stands for no data.  
 
Excipient % Inhibition of CDV % Inhibition of CAV2 Tm (oC) for CPI 
Virus Alone 0 0 52.8 
0.2M Sodium Citrate 113 14 56 
0.3 M Arginine 108 45 49.9 
7.5E-6 M Dextran Sulfate 94 66 52.9 
 20% Dextrose  77 69 57.0 
10% 2-OH propyl g-CD 73 11 52.6 
20% Sucrose 69 67 57.3 
20% Sorbitol 67 114 57.5 
20% Glycerol 62 38 56.3 
0.3M Lysine 62 85 53.3 
10% 2-OH propyl β-CD 55 18 50.9 
20% Trehalose 53 -47 55.0 
10% Mannitol 53 ND 55.0 
.15M Malic Acid 48 8 52.6 
.15M Lactic Acid 41 -26 52.6 
.15M Aspartic Acid 40 -52 52.6 
0.3M Guanidine 27 -111 47.2 
0.3M Dietanolamine 17 26 52.3 
0.3M Proline 17 -46 52.6 
0.1% Tween 80 16 63 52.6 
0.3M Glycine 15 ND 51.3 
.15M Ascorbic acid 14 ND 52.6 
7.5E-6 M  Dextran T70 6 -27 52.6 
0.1% Brij 35 5 14 51.3 
0.1% Tween 20 0 21 52.7 
0.1% Pluronic F-68 0 -2 52.6 
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Table 4.2: The effect of concentration of selected stabilizers on the thermal unfolding 
temperature (Tm) values of CDV, CPI and CAV2 viruses as determined by circular dichroism 
spectroscopy (in the case of CDV and CAV2) and intrinsic fluorescence spectroscopy (in the 
case of CPI) in a 20 mM citrate phosphate buffer at pH 7. Standard error was calculated to be 
±0.5oC. ND stands for no data.  
 
 
 
Excipient Tm (°C) for CDV 
Tm (°C) 
for CPI 
Tm (°C) for 
CAV2 
CDV2 49.4 52.7 56.0 
25% Sorbitol 62.5 55.8 57.0 
20% Sorbitol 56.4 57.5 ND 
15% Sorbitol 55.6 55.3 59.1 
10% Sorbitol 53.6 54.6 57.5 
5% Sorbitol 52.5 52.8 55.0 
25% Sucrose 54.9 56.8 56.5 
20% Sucrose 54.2 56.8 ND 
15% Sucrose 49.8 55.2 56.5 
10% Sucrose 51.1 54.4 53.0 
5% Sucrose 50.0 53.9 56.1 
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Figures 
 
 
Figure 2.1. Circular dichroism spectrum of HAC1 at 10 °C. 
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Figure 2.2. Circular dichroism thermal melt plots of HAC1 in imidazole buffer. The molar 
ellipticity at 222 nm was monitored as a function of temperature for six pH conditions—pH 3.0 
(A), 4.0 (B), 5.0 (C), 6.0 (D), 7.0 (E) and 8.0 (F).  
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Figure 2.3. Intrinsic fluorescence peak position changes as a function of temperature for the pH 
range 3.0-8.0. Peak positions are determined by the mean spectral center of mass (msm) method, 
which shifts the actual peak positions by 8-10 nm towards the red.  
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Figure 2.4. Static light scattering intensity changes as a function of temperature for the pH range 
3.0-8.0. Static light intensity was determined by monitoring scattered light at the fluorescence 
excitation wavelength (295 nm).  
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Figure 2.5. ANS fluorescence intensity changes as a function of temperature for the pH range 
from 3.0-8.0 for HAC1. Peak intensities are determined by the mean spectral center of mass 
(msm) method.  
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Figure 2.6. An empirical phase diagram (EPD) constructed using intrinsic and extrinsic 
fluorescence, circular dichroism and static light scattering techniques for HAC1. 
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Figure 2.7. Comparison of thermal unfolding profiles of HAC1 in the presence of selected 
different stabilizers and destabilizers. Excipients are prepared in imidazole buffer (10 mM 
imidazole, pH 7.0, I=0.15 M adjusted with NaCl). 
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Figure 2.8. Desorption of HAC1 from adjuvant surface. Over 80% of HAC1 is desorbed from 
Alhydrogel® in the presence of a combination of 0.9 M sodium citrate and 1.8 M urea. The error 
bars reflect the standard deviations based on three different experiments. 
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Figure 2.9. Effect of selected stabilizers on the adsorption of HAC1 onto Alhydrogel®. 
Alhydrogel® was added to the mixture of HAC1 and the excipient. The error bars reflect the 
standard deviations based on three different experiments 
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Figure 2.10. Intrinsic fluorescence based melting curves of HAC1 in the presence of selected 
excipients and Alhydrogel®. The excipients shown here were selected by screening in liquid 
formulations. 
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Figure 2.11. Intrinsic fluorescence based melting curves of HAC1 in the presence of best 
stabilizers identified for adjuvanted formulation. The error bars reflect the standard deviations 
based on three different experiments. 
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Figure 2.12. Intrinsic fluorescence based melting curves of annealed HAC1 in the presence of 
Alhydrogel®.  
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Figure 2.13. Hemagglutination-inhibition (HAI) antibody titers in sera from immunized mice. HAI 
titers are expressed as mean titers for each immunization group with standard deviations. Samples 
without detectable HAI were assigned a titer of 1:10.  
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Figure 3.1: Biophysical characterization and excipient screening for protein antigen SP1650. (A) CD 
spectra of SP1650 at different pH values at 10oC, (B) CD melts of SP1650 at different pH values, (C) 
Intrinsic fluorescence peak position shifts for SP1650 as a function of pH and temperature, (D) Intrinsic 
fluorescence peak intensity changes for SP1650, (E) Extrinsic fluorescence peak intensity changes for 
SP1650 using ANS, (F) Static light scattering intensity shifts as a function of pH and temperature, (G) 
Empirical phase diagram for SP1650, and (H) Intrinsic fluorescence peak position shifts for SP1650 in 
the presence of selected excipients. 
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Figure 3.2: Biophysical characterization and excipient screening for protein antigen SP1732. (A) CD 
spectra of SP1732 at different pH values at 10oC, (B) CD melts of SP1732 at different pH values, (C) 
Intrinsic fluorescence peak position shifts for SP1732 as a function of pH and temperature, (D) Intrinsic 
fluorescence peak intensity changes for SP1732, (E) Static light scattering intensity shifts as a function of 
pH and temperature, and (F) Empirical phase diagram for SP1732. 
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Figure 3.3: Biophysical characterization and excipient screening for protein antigen SP2216. (A) CD 
spectra of SP2216 at different pH values at 10oC, (B) CD melts of SP2216 at 222 nm at different pH 
values, (C) Static light scattering intensity shifts as a functions of pH and temperature, (D) Extrinsic 
fluorescence peak intensity changes using ANS, (E) second derivative UV melts of SP2216 as a function 
of pH and temperature, and (F) Empirical phase diagram for SP2216. 
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Figure 3.4: Percent adsorption of the three protein antigens (SP1650, SP1732, SP2216) to two different 
aluminum salt adjuvants, Alhydrogel and Adjuphos. 70 µg of protein was adsorbed onto 50 µg of 
adjuvant in a 10 mM sodium acetate buffer at pH 5.5. 
 
 
 
 
 
 
 
 
126	  
	  
 
 
 
Figure 3.5: Adsorption isotherms for the three protein antigens (SP1650, SP1732, SP2216) to aluminum 
hydroxide adjuvant (Alhydrogel) in a 10 mM sodium acetate buffer at pH 5.5.  
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Figure 3.6: Intrinsic fluorescence emission maximum as a function of temperature for SP1650 in solution 
and while adsorbed to Alhydrogel in a 10 mM sodium acetate buffer at pH 5.5. The effect of manganese 
on protein stability in solution and in presence of Alhydrogel is shown along with the effect phosphate on 
the stability of the adsorbed protein.  
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Figure 3.7: Intrinsic fluorescence emission maximum as a function of temperature for SP1732 in solution 
and on Alhydrogel in a 10 mM sodium acetate buffer at pH 5.5. 
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Figure 3.8: Representative tryptophan fluorescence spectra of SP2216 at 10°C in solution and adsorbed 
to the adjuvant.  
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Figure 3.9: FTIR Second derivative peak intensity changes at 1620 cm-1 as a function of temperature for 
SP2216 in solution and on Alhydrogel in a 10 mM sodium acetate buffer at pH 5.5. 
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Figure 3.10: Desorption of the three protein antigens from aluminum hydroxide adjuvant (Alhydrogel). 
SP1650 was desorbed from adjuvant using a solution containing 1M sodium citrate and 2M urea. SP1732 
and SP2216 were desorbed using 2M Guanidine.  
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Figure 3.11: Representative second derivative FTIR spectra of SP2216 at different temperatures in a 
10mM sodium acetate buffer at pH 5.5.  
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Figure 4.1. TEM images of three live attenuated canine viruses after purification (A) CDV,(B) CPI and 
(C) CAV2, along the SDS-PAGE gel image of the  individual purified virus samples (D) CDV,(E) CPI 
and (F) CAV2. The marker for the gels is shown on the left along with the virus samples on the right. 
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Figure 4.2. Biophysical characterization data for the purified canine distemper virus in a 20 mM citrate 
phosphate buffer. (A) CD spectrum of CDV at pH 7 and 10oC. (B) CD signal at 222 nm, (C) changes in 
fluorescence peak position as analyzed by MSM, and (D) changes in the static light scattering intensity at 
different pH values as a function of temperature. Error bars are not included for clarity of data.  
D	  C	  
B	  
A	  
135	  
	  
 
 
Figure 4.3. Biophysical characterization data for purified canine parainfluenza virus in a 20 mM citrate 
phosphate buffer. (A) CD spectrum of CPI at pH 7 and 10oC. (B) CD signal at 222 nm, (C) changes in 
fluorescence peak position as analyzed by MSM, and (D) changes in the static light scattering intensity at 
different pH values as a function of temperature. Error bars are not included for clarity of data. 
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Figure 4.4. Biophysical characterization data for purified canine adenovirus type 2 in a 20 mM citrate 
phosphate buffer. (A) CD spectrum of CAV2 at pH 7 and 10oC. (B) CD signal at 222 nm, (C) changes in 
fluorescence peak position as analyzed by MSM, and (D) changes in the static light scattering intensity at 
different pH values as a function of temperature. Error bars are not included for clarity of data. 
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Figure 4,5. Empirical phase diagrams constructed for three different purified live attenuated canine 
viruses:  (A) CDV (B) CPI and (C) CAV2. The red color represents the CD (secondary structure) data, the 
green represents the intrinsic fluorescence (tertiary structure) data and the blue represents the protein 
association (aggregation) data. The white and yellow regions represent the native state of the virus. The 
blue regions represent an aggregated state of the virus, pink region in the CPI virus represents a state 
where the viral proteins of the virus are unfolded.  
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Figure 4.6. Excipient screening data for two purified live, attenuated canine viruses.  (A and C) CDV 
virus stability as monitored by aggregation at OD350nm and thermal unfolding temperature (Tm) by 
circular dichroism.    (B and D) CPI virus stability monitored by Tm values from fluorescence 
spectroscopy.  Virus samples contained indicated level of excipients in a 20 mM citrate phosphate buffer 
at pH 7.  
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